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1. Abbreviations 
 
6MWT  six-minute walk test 
ACh   acetylcholine 
ACEi   angiotensin converting enzyme inhibitor 
Ac-LDL  acetylated low density lipoprotein 
AE   adverse event 
Akt   protein kinase B 
ALS   amyotrophic lateral sclerosis 
BB   beta receptor blocker 
BM   bone marrow 
BNP   B-type natriuretic peptide 
BOEC   Blood outgrowth endothelial cells 
cDNA   complementary deoxyribonucleic acid 
CGMP  current good manufacturing practice 
CM   cardiomyocytes 
CSC   cardiac stem cells 
DAPI   4', 6-diamidino-2-phenylindole - dihydrochloride 
DCM   dilated cardiomyopathy 
DLL4   Delta-like ligand-4 
DMSO  dimethyl-sulfoxide 
EB   embryoid body 
EC   endothelial cells 
EBM   endothelial basal medium 
ECM   extracellular matrix 
EGM   endothelial growth medium 
EHT   engineered heart tissue 
ELISA  enzyme-linked immunosorbent assay 
ET-1   endothelin-1 
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eNOS   endothelial nitric oxide synthase 
EPC   endothelial progenitor cells 
ERC   endometrial regenerative cells 
FACS   fluorescence-activated cell sorting 
FDA   Food and Drug Administration 
FOXO1A  Forkhead box O transcription factor 1A  
FBS   foetal bovine serum 
GABA  gamma amino butyric acid 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GVHD  graft-versus-host disease 
HAEC  human aortic endothelial cells 
HCAEC  human coronary arterial endothelial cells 
hESC   human embryonic stem cells 
hESC-EC  human embryonic stem cells -derived endothelial cells 
hESC-CM  human embryonic stem cells-derived cardiomyocytes 
HFpEF  heart failure with preserved ejection fraction 
hiPSC   human induced pluripotent stem cells 
hiPSC-EC  human induced pluripotent stem cells-derived endothelial cells 
HLA   human leucocyte antigen 
HOCM  hypertrophic obstructive cardiomyopathy 
hPSC   human pluripotent stem cells 
HUVEC  human umbilical cord endothelial cells 
I-DCM  ischemic dilatative cardiomyopathy 
iNOS   inducible nitric oxide synthase 
ITGB1  integrin beta-1  
IVF   in vitro fertilisation 
LVEF   left ventricular ejection fraction 
MI   myocardial infarction 
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MLHFQ  Minnesota living with heart failure questionnaire 
MRI   magnetic resonance imaging 
MSC   mesenchymal stem cells 
MS   multiple sclerosis 
NA   not applicable 
NEC   non-enzyme control 
nNOS   neural nitric oxide synthase 
NOS   nitric oxide synthese 
NTC   non-templates control 
PBS   phosphate buffered saline 
PCI   percutaneous coronary intervention 
PCR   polymerase chain reaction  
PDGFRA   platelet-derived growth factor receptor alpha 
PI3K   phosphatidylinositol-4, 5-bisphosphate 3-kinase 
PIK3R1  phosphoinositide-3-kinase regulatory subunit 1 beta 
PIK3R2   phosphoinositide-3-kinase regulatory subunit 2 beta 
PPP   platelet poor plasma 
PRKCA   protein kinase C alpha  
PRKCB   protein kinase C beta 
PRKCZ   protein kinase C zeta  
PRP   platelet rich plasma 
PSC   pluripotent stem cells 
PSC-EC  pluripotent stem cell-derived endothelial cells  
PTEN   phosphatase and tensin homolog 
qRT-PCR  quantitative real-time polymerase chain reaction 
rh-bFGF  recombinant human basal fibroblast growth factor 
rh-TGFβ  recombinant human transforming growth factor beta 
RNA   ribonucleic acid  
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siRNA   small interfering RNA  
SNP   sodium nitroprusside 
SPECT  single-photon emission computed tomography 
STEMI  ST segment elevation myocardial infarction 
VEGF   vascular endothelial growth factor 
vWF   von Willebrand factor 
WBC   white blood cells 
WSS   wall sheer stress  
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2. Introduction 
 
2.1.  Current applications and future challenges in cell therapy 
 
Cell therapy is the focus of medical research for developing novel therapeutic 
strategies. Degenerative diseases affect large number of patients placing high burden on 
health and social care systems. Many patients suffer from severe neurodegenerative 
diseases (e.g. Parkinson‟s disease, amyotrophic lateral sclerosis (ALS), and multiple 
sclerosis (MS)) and ischemic cardiovascular events (stroke or myocardial infarction (MI)). 
Cardiovascular diseases are the leading cause of death in industrialised countries. 
Pathophysiology of these diseases involves definitive necrosis of cells with a crucial role in 
the physiology of the human body (circulation, central or peripheral nervous system). The 
regenerative capacity of neurons is limited, similarly as cardiomyocytes [1, 2]. Many 
patients suffer severe decrease in quality of life due to a lack of definitive treatment. 
Insulin-dependent diabetes mellitus may develop in very young children and so far no 
definite therapy exists; treatment options focus on substitution of pancreatic β cell product, 
insulin. Preclinical research and early cell therapy trials are underway in these medical 
conditions. Regenerative medicine and tissue engineering may establish definitive 
treatments to cure these conditions. 
Cell therapy is being routinely used in special clinical conditions. Bone marrow 
transplantation is performed frequently in haemato-oncological diseases, e.g. leukaemia 
and lymphomas.  It is carried out through both autologous and allogeneic route.  
In severe graft-versus-host disease (GVHD) mesenchymal stem cells (MSC)-derivatives 
are transplanted if the condition is resistant to steroid shot therapy. The Remestemcel-L
®
 
(Prochymal, Osiris) product is available in the US and Canada, and was approved by the 
FDA. Remestemcel-L
®
 contains MSC from healthy adults, and applied intravenously in 
GVHD. Remestemcel-L
®
 is a novel, of-the-shelf available cell therapy [3]. 
Umbilical cord blood contains multipotent stem cells (mononuclear haematopoietic stem 
cells and mesenchymal stromal cells), similar to MSC. Several commercial companies are 
offering collection and bio-banking of umbilical cord blood after birth. The treatment costs 
can be extremely high. These companies promote umbilical blood bio-banking as a 
procedure that could provide life-saving therapy in a theoretical future malignant haemato-
oncological disease. However, the literature is lacking in data on autologous 
DOI:10.14753/SE.2016.1894
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transplantation of these precursor cells in malignant conditions. There is growing evidence 
supporting the theory that life-threatening hemato-oncological diseases are clonal diseases. 
This means that the multipotent precursor itself may carry malignant mutations. Albeit, 
collection of umbilical cord blood cells may serve public health purposes, HLA typization 
may enhance their widespread use. In the USA five umbilical cord blood products have 
received FDA approval so far for hemato-oncological therapeutic use. In Hungary, two 
allogeneic transplantations were performed using umbilical cord blood-derived precursor 
cells [4]. 
In recent years, new stem cell-derivatives have already been tested in various clinical 
conditions. Pluripotent stem cells show magnificent promises for tissue regeneration. 
Pieces of the mosaic in their future therapeutic palette involve recovery of motoneuron 
function after spinal cord injury or in neurodegenerative diseases, developing insulin 
producing β cells and regenerating the failing human heart. 
Geron (Asterias Biotherapeutics) has initiated the first-in-human clinical trial with human 
embryonic stem cells (hESC) (NCT01217008) [5]. The phase I trial investigated the safety 
of hESC-derived oligodendrocytes implantation after spinal cord injury [6]. Administration 
of the stem cell product required continuous immunosuppression, as hESC-derivatives 
were allogenic. The trial recruited a small number of patients (n=10) due to large financial 
burden; the trial was terminated early for the same reason. Published safety results have 
not reported any surgical or neurologic adverse events (AE). Most AEs were as a result 
from immunosuppressive medication.  
Another novel breaktrough in cell therapy was the development on donor type 0, Rh 
negative red blood cells from human pluripotent stem cells. A research group at Glasgow 
University has been working on this project [7]. Fulfilling the transfusion need with 
healthy blood donors is limited in many countries in the EU. The recently developed type 
0, Rh negative red blood cells promise blood available off-the-shelf for transfusion, and 
researchers plan first-in-human transplantation in 2020 in the UK. The hESC-derived red 
blood cells function similarly to those isolated from bone marrow [8, 9]. However, 
directing the enucleation of cells and haemoglobin switch may be challenging during 
differentiation process. Large-scale engineering also promotes further development in 
differentiation procedure [10]. Immunological consideration is required, as these red blood 
cells are derived from hESC and may initiate immunological responses during allogeneic 
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transplantation. Human ESC derivatives may possess unexpected immunological 
properties [10-12]. 
Another field of medicine where cell therapy paves the way with novel therapeutic 
products, is ophthalmology. Holoclar contains limbal epithelial stem cells. These cells are 
isolated from the edge of the cornea and are responsible for corneal regeneration. Holoclar 
is transplanted autologous after chemical injury of the cornea, authorised by EU 
regulations. Pluripotent stem cell-derivatives are being used in several ophthalmological 
clinical trials. The eye is thought to be an immunologically special and protected organ in 
the human body. Human ESC derivatives transplanted into the macular region of retina are 
feasible without rejection or tumour formation complications. There are many clinical 
trials underway, collecting human samples for the generation of human induced pluripotent 
stem cells (hiPSC) in retinoblastoma (NCT02193724). Other trials are investigating 
putative beneficial effects of cell therapy in bestrophinopathy (NCT02162953), age-related 
macular degeneration (NCT01674829), macular dystrophy (NCT01469832) and myopic 
macular degeneration (NCT02122159). 
Many clinical trials are enrolling patients in other special medical conditions (type 1 
diabetes mellitus (NCT02084407), ALS (NCT00801333), ataxia teleangiectasia 
(NCT02246491), Barth syndrome (NCT01625663)) to collect human samples (especially 
fibroblasts) for hiPSC generation. Patients-derived hiPSC provide chance for investigating 
pathophysiology of diseases in vitro. Furthermore hiPSC offer personalised drug testing in 
vitro. The first clinical trial with hiPSC has already started in Japan [13]. Elderly patients, 
suffering from age-related macular degeneration receive autologous hiPSC-derived retinal 
pigment epithelial implantation. The hiPSC-derived retinal epithelial cells are grown in cell 
sheets to enable ophthalmic surgical procedures. The preclinical animal experiments 
demonstrated no tumorigenic potential of hiPSC-derived retinal pigment epithelial 
implantation on the long run [10, 14]. Altough first patient has already been treated without 
any significant adverse events so far [13] the trial was recenlty suspended. Single- 
nucleotid variations and copy-number variations were found in hiPSC of the second 
patient. These genomic abnormalities were not detected in the original fibroblasts. Impacct 
of these findings on the future of hiPSC clinical trials is not yet clear [15].  
Following the early steps of cell therapy the clinical use still faces many challenges and 
open questions.  My PhD thesis focuses on cardiovascular derivatives of human pluripotent 
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stem cells, especially on endothelial cells. Preclinical results and early clinical trials with 
cell therapy in cardiovascular field will be discussed in details later in section 2.3. Figure 1. 
summarizes cell therapy approaches in regenerative cardiac medicine. 
 
Figure 1. Experimental approaches to cell therapy in heart failure Figure shows 
experimental approaches, cell types and cell delivery routes for regenerative purposes in 
heart failure (Figure is from Kosztin/Gara et al. Stem cell therapy to treat heart failure 
Elsevier 2015, Reference Module in Biomedical Sciences)  
 
The key aims of cardiovascular cell therapy are: 
 
1) to prevent myocardial loss during myocardial tissue injury (ischaemic attacks, 
cardiomyopathy, valve diseases, etc.); 
2) to decrease the ratio of definite necrosis after ischemic events and salvage stunned 
myocardium; 
3) to decrease the rate of remodelling, and enhance reverse remodelling after 
myocardial injury; 
4) to support angiogenesis during and after ischemic attack; 
5) and to regenerate myocardial tissue in severe heart failure from different 
aetiologies. 
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Regarding cell therapy and translational research in the cardiovascular field many 
questions remain open: 
1) Which is the ideal cell type for cell therapy?  
Circulating progenitor cells, multipotent stem cells, cardiac progenitor cells 
 and pluripotent stem cell-derivatives are candidates. 
 
2) How to perform the cell implantation? 
Applications: direct surgical implantation, surgical cardiac patches, local intra-
myocardial injection, intracoronary injection, coronary sinus injection, systemic 
intravenous injection, use of bioscaffolds for cell engineering and implantation. 
 
3) What is the ideal number of cells for implantation? 
Early clinical studies lack valuable information about the required amount of 
implanted cells. To build up a human adult heart, ~ 6 billion cells may be needed. 
The left ventricle is made up from ~ 4x10
9
 cardiomyocytes (2x10
6
/g of tissue, the 
whole heart is ~300g) [16]. In a large MI ~ 10
9 
cardiomyocytes suffer irreversible 
damage. State-of-the-art clinical imaging systems (e.g. SPECT-CT) may estimate 
the number of cells needed for regeneration before performing transplantation. 
Considering personalised regenerative therapy with hiPSC-derivatives, the amount 
of injected cell should also be adjusted individually.  
 
4) How to track injected cells after implantation to enable ability of following their 
fate in vivo? 
The vast amount of transplanted cells seem to be washed out from the target tissue 
via venous and lymphatic circulation and imaging their homing in vivo is still a 
challenge. In most preclinical studies, the data are lacking about the amount of cells 
engrafted into the myocardium. Furthermore, no information exists about what 
happens to non-hosting cells. As clinical trials typically follow up the patients for a 
short period (two years), long term data is missing on attainable tumour formation 
or pro-carcinogenic considerations.  
DOI:10.14753/SE.2016.1894
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5) What is the ideal timing for cell implantation? 
Clinical studies are inconclusive regarding the timing of cell therapy. Scientific 
knowledge is lacking regarding the best timing for anticipated beneficial 
regenerative effects. Some trials aim to treat in the acute phase of cardiovascular 
events, e.g. within one week after myocardial infarction. Others aim regeneration 
late after the myocardial event, e.g. in end-stage heart failure.   
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2.2.  Types of stem cells 
 
2.2.1.  Circulating progenitor cells 
 
In cardiovascular diseases the pathological steps are endothelial dysfunction and 
damage. Circulating endothelial progenitor cells (EPC) are in the focus of research for over 
a decade, providing possible source for therapeutic re-endothelisation and endothelial 
repair [17]. Furthermore, EPC were nominated to be biomarkers for cardiovascular risks 
and disease progression [18]. Many studies have also considered EPC to be putative 
biomarkers for pathological conditions [19]. The amount of circulating EPC is proposed to 
be biomarker for the progression of atherosclerosis and for coronary plaque characteristics 
[20, 21].  After promising early studies, recently published data have been controversial 
regarding the role of EPC as biomarkers. Data are also diverse regarding therapeutic 
considerations [17].  
EPC were first characterised in 1997 [22] and early studies demonstrated them to be bone 
marrow derived, CD34-positive cells. Despite great efforts, no clear definition is available 
on these progenitor cells. In fact, data are confusing on titles and subgroups of EPC, 
naming them such as “circulating angiogenic cells”, “endothelial colony forming cells” and 
“colony forming unit cells” [17]. EPC are mainly characterised by the presence of cell 
surface markers: CD34, VEGFR2, CD133, ICAM-1 and E-Cadherin, with flow cytometry. 
Isolation protocols are also available that group EPC to early and late outgrowth 
population [19, 23, 24]. In 2004 EPCs have been therefore redefined [25]. Population of 
cells from human peripheral blood were expanded in vitro, which expressed CD31 and 
vWF. In addition, these cells showed cobblestone morphology in culture which is 
characteristic for endothelial cells. It was proved that these human cells have the capacity 
to form chimeric human-murine vessels when implanted subcutaneously into mice [25]. 
Their role in adult organism was thought to be the enhancement of angiogenesis in adults 
[26]. Indeed, a number of clinical studies in humans show the activation or injection of 
these cells. Whether these cells contribute directly to new vessel formation or simply 
support that by cytokine release and the rate of beneficial effects remains unclear [19].  
In a prominent phase II, randomised clinical trial patients with type 2 diabetes mellitus and 
hyperlipidaemia discontinued statin treatment for a short period and meanwhile changes in 
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EPC levels and angiogenic function were measured [27]. The results were impressive, as 
large increases were detected in the levels of circulating EPC and in their functional 
activity, after 5 days of statin discontinuation [27]. The data suggest that EPC may have an 
important role in atherosclerotic disease progression and therapeutic efforts for endothelial 
repair and re-endothelisation [27]. However, more investigations are needed to understand 
exact function of EPC and their role in vascular biology. 
 
2.2.2.  Mesenchymal stem cells 
 
MSC are either derived from the bone marrow or from peripheral organs. MSC 
were first described in 1970 as nucleated cells in the bone marrow and were known to be 
responsible for steady-state circumstances in the bone marrow niche [28].  
MSC are able to differentiate into multi-lineage derivatives and are able to perform self-
renewal. Thus, they were named as mesenchymal stem cells, albeit recent publications 
rather call them mesenchymal stromal cells [29, 30]. The early clinical trials used many 
different types of MSC-like cells which were not precisely characterized. To enhance 
standardised characteristics of MSC in translational research and early phase clinical trials, 
strict requirements were set up for MSC definition [31]. In 2006, the International Society 
for Cellular Therapy published MSC definitions: 
 
 Adherence to plastic surface in standard culture conditions 
 Expression of the following cell surface markers: CD73, CD90, and CD105  
 Absence of the following cell surface markers: CD34, CD45, HLA-DR, CD14 or 
CD11b and CD79a or CD19  
 Ability to differentiate to osteoblasts, adipocytes, and chondroblasts in vitro [31]. 
 
Sources of MSC isolation and collection are the bone marrow and peripheral organs. These 
include adipose tissue and many other organs like the liver, placenta, gut, lung, heart and 
even amniotic fluid, dental pulp, periodontal ligament or Wharton jelly of the umbilical 
cord. Many studies use adipose tissue-derived MSC, as their collection is easier and more 
feasible. Wharton jelly-derived MSC were also studied in many trials [32]. MSC from 
different sources possess many differences in genotype and phenotype.  MSC derived from 
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the amniotic fluid express pluripotency marker SSEA4. MSC-like cells isolated from heart 
tissue express myogenic markers and tend to be myogenic precursor cells [33].  
Despite the improvement of protocols, the isolation and expansion of MSC are still with 
low efficacy. For clinical therapeutic use the isolation and expansion requires therefore 
better and CGMP competent protocols. From 10ml of bone marrow aspirate 50-400 x 10
6
 
MSC can be isolated. Huge variation exists in elderly population and in case of co-
morbidities.  
MSC are elongated, fibroblast like cells which grow on plastic in MSC medium. MSC can 
differentiate into chondrocytes, osteoblast, myocyte precursor cells and adipocytes in vitro, 
although the differentiation rate is low. Beside direct use of cells for therapy, studies also 
focus on the indirect anti-inflammatory and paracrine effects of MSC. The favourable 
effect of MSC for therapeutic purposes may be their anti-inflammatory and anti-fibrotic 
role. These cells have been shown to secrete wide range of proteins which would promote 
regenerative angiogenesis and stimulate endogenous cardiac regeneration in vivo [33]. In 
post-MI failing myocardium, two major types of macrophages are present in the injured 
myocardium. Type M1is responsible for the production of pro-inflammatory proteins, 
debris degradation and apoptosis. Type M2 has anti-inflammatory role and supports early 
angiogenesis. After MI, in the presence of MSC, the number of type M2 macrophages 
increase [34, 35]. MSC have cardioprotective effects and can decrease size of scar after 
MI. For this, they may enhance the survival rate in stunned myocardium and decrease 
necrosis. Detailed studies showed, cardiac cytoprotection occurs by modulating key 
signalling pathways, which include the Wnt, IGF1-NF-kB, Akt1 and TGFβ pathways [36-
39]. For cardiac regeneration and repair, MSC share pleiotropic mechanisms of action 
(Table 1.) [8]. However, limitations and controversial effects of MSC reside in formation 
of mesoderm-derived ectopic cells and enhancement in fibrosis may progress in vivo [40]. 
Clinical trials with MSC in cardiovascular field are discussed in details in section 2.3.2. 
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Table 1. Mechanisms of action of mesenchymal stem cells in cardiac regeneration 
Table shows putative effects and mechanisms of action of mesenchymal stem cells in 
cardiac regeneration (WBC: white blood cells, ECM: extracellular matrix) 
Effect Mechanism  
Immunomodulation Supressing WBC, enhancing M2 type macrophages 
Antifibrosis Modulation of ECM niche by paracrine effects 
Pro-angiogenesis Secretion of pro-angiogenic proteins and molecules 
Pro-neomyogenesis Activation of cardiac resident stem cells and progenitors 
Cardiac cytoprotection Modulating signalling pathways, anti-apoptotic effects 
Direct cellular effects Differentiation to cardiac myogenic precursor cells 
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2.2.3.  Cardiac stem cells 
 
Resident, adult stem cells occur in many organs and tissues of the human body. The 
main role of adult stem cells may be their participation in physiological turn-over of tissues 
as well as support of endogenous regeneration after tissue injury. In the cardiovascular 
system, endothelial and cardiac progenitor cells stand for adult stem cells. Adult, resident 
stem cells (CSC) in the myocardium are clonogenic, have the ability for self-renewal and 
may differentiate to any cardiovascular cell type (cardiomyocytes, endothelial cells and 
smooth muscle cells) [41, 42]. However, their exact role in cardiac regeneration and their 
potential to improve decreased cardiac function is still controversial. Scientific knowledge 
is diverse regarding the role of CSC in the physiologic turnover of the myocardium [41, 
43-45]. Some resident CSC may re-enter cell-cycle and replace damaged or dysfunctional 
cardiomyocytes. The main characteristics of CSC cells are c-kit positivity; further 
characteristics can include positivity for islet-1, Nkx-2.5 and MEF-2c (cardiac progenitor 
markers). C-kit is a tyrosine kinase receptor (also known as CD117), which binds SCF 
(stem cell factor) and involved in many important signalling pathways, including the PI3K 
and ERK, mainly responsible for cell proliferation and migration [46-48]. The origin of c-
kit positive CSC in the adult heart is not clear. Some studies showed their origin may be 
the cardiomyocytes and epicardial cells of the heart and CSC develop by dedifferentiation 
and epicardial-mesenchymal transdifferentiation [49, 50]. Other groups showed that CSC 
may arise from circulating progenitor cells and home to the adult heart [51, 52]. Further 
studies report that CSC preserved stem cell niche during embryonic cardiomyogenesis [53, 
54]. Many studies have been investigating potential role of CSC in cardiac regeneration 
and repair. Similarly to MSC, CSC have multimodal mechanisms to enhance cardiac repair 
[53]. Their paracrine effects incluede secretion of pro-angiogenic, anti-apoptotic factors 
and supporting angiogenesis after ischemic injury. The direct cellular effects contain 
differentiation to early/late cardiac progenitors or cardiomyocytes (most controversial 
field). 
Preclinical results and clinical trials investigating CSC in cardiovascular field are discussed 
in details in section 2.3.3. 
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2.2.4.  Embryonic stem cells 
 
Human ESC were first established in 1998, by James Thomson et al., in Wisconsin 
[55]. Inner cell mass of the blastocyst were isolated and embryonic stem cells were plated. 
Thomson used five blastocysts remaining from in vitro fertilisation (IVF) procedure, 
fourteen samples from inner cell masses were isolated and the first five hESC lines were 
established. Today over 1000 hESC lines exist [56, 57]. Ethical regulations are diverse 
regarding the development and use for research purposes of hESC (detailed in section 
4.12.). Early protocols for inner cell mass isolation from the blastocyst resulted in the 
destruction of the embryo. Mechanical isolation, surgical isolation and even laser 
techniques have been developed [58-60]. Recent isolation procedures are enable to rescue 
the embryo, thus ethical concerns may be reduced [61].  Human ESC lines were 
successfully developed from single blastomeres by routine biopsies performed for 
preimplantation genetic testing during IVF [62-64]. These derivation protocols are facing a 
number of challenges, regarding the distinct phenotype and genotype of the developed 
hESC lines [65].  
Human ESC can expand unlimitedly with asymmetric self-renewal while preserving 
normal karyotype and pluripotent state. During directed differentiation, hESC are able to 
give rise to all three germ layers (ectoderm, endoderm and mesoderm) and for germline, 
except extra-embryonic tissues of the placenta (trophoectoderm) (Figure 2.). Human ESC 
are able to differentiate into all tissue and cells in human organism: ectoderm derived 
neurons [66], Schwann cells [67], melanocytes [68], skin cells [69]; endoderm derived 
hepatocytes [70], intestinal cells [71], pancreatic cells [72], pneumocytes [73]; mesoderm 
derived blood cells [74], fibroblasts [75], adipocytes [76], smooth muscle cells [77], 
cardiomyocytes [78], endothelial cells [79], etc. Upon in vivo transplantation of hESC they 
spontaneously form teratomas. For in vitro colony formation, hESC require special cell 
culture conditions. Early protocols included xenogenic feeder cells and growth factors; 
later xeno-free feeder culture conditions developed. Recently hESC have been grown on 
ECM components in xeno-free conditions (eg. laminin, fibronectin, vitronectin, Matrigel) 
in commercially available predefined media for pluripotent cells [65]. Human ESC are 
characterized by cell surface markers and transcription factors associated with 
pluripotency. Briefly, these pluripotency markers are TRA1-60/81, TRA2-49/54, CD-
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9/24/29/49f/324/338 and SSEA-1/3/4/5 (cell surface proteins) and transcription factors 
Oct-4, Nanog, Stat-3, FoxD3, c-Myc and Sox-2 [65]. Translational studies with hESC in 
the cardiovascular field are discussed in section 2.3.4. in details. 
 
 
 
Figure 2. Human embryonic stem cells and derivatives Figure shows origin of human 
embryonic stem cells, these pluripotent stem cells are able to differentiate into any cell 
types of the three germ layers and germline (original figure from Edit Gara)  
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2.2.5.  Induced pluripotent stem cells 
 
In 2006 Japanese researcher Shinya Yamanaka, and his group successfully 
developed mouse pluripotent stem cells from adult somatic cells, by using genetic 
reprogramming [80]. The first hiPSC line was developed in 2007, parallel by two 
independent research groups: Yamanaka et al. and Thomson et al. [81, 82]. The idea of 
nuclear transfer itself, existed earlier, notably Dolly the sheep was born through the nuclear 
transfer cloning method [83].  Forced expression of specific genes in differentiated somatic 
cells has been shown to reverse the developmental program in adult somatic cells; this 
process is called reprogramming. When using reprogramming method, nuclear transfer or 
oocyte manipulation is not necessary to induce genome modification. During 
reprogramming, genes responsible for pluripotency are inserted into the genome of adult 
somatic cells by transfection. These pluripotency genes are named Yamanaka factors or 
master genes: Oct-3/4, Sox-2, Klf-4 and c-Myc [80]. Oct-3 and 4 play a key role in early 
embryonic development and in maintaining pluripotent fate is stem cells. Sox-2 is 
responsible for continuous self-renewal in pluripotent stem cells. Klf-4 is also involved in 
maintenance of pluripotency, proliferation and cell survival. Myc is known to be an 
oncogenic regulator, tumour suppressor and is affected in almost all human cancers. Myc 
plays a crucial role in physiologic operation of cell cycle and proliferation [84].  
Human iPSC promise wide range of new possibilities in basic research, translational 
medicine and therapy. Human iPSC offer specific cell types for modelling diseases, testing 
drug toxicology and developing drugs in vitro, even in a patient-specific manner. Human 
iPSC have similar characteristics to those of embryonic stem cells, as they express same 
pluripotency markers and can differentiate into all three germ lines [85] (Figure 3.). 
Indeed, undifferentiated hiPSC were shown to form teratomas in vitro [80]. Human iPSC 
may later be the most efficient and feasible option for tissue engineering therapeutic 
perspectives. Ongoing preclinical studies with hiPSC will be discussed in details in section 
2.3.5. 
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Figure 3. Induced pluripotent stem cells and derivatives Figure shows the derivation of 
human induced pluripotent stem cells. These pluripotent stem cells are able to differentiate 
to any cell types of the three germ layers and germline (original figure from Edit Gara) 
 
Due to the great translational and clinical potential, hiPSC are in the focus of basic 
research. The reprogramming method itself determines the fate and phenotype of the 
developed pluripotent cells, also the donor cell line influences reprogramming. Several 
reprogramming techniques were established in the last decade with a large variability in 
safety and efficacy profile [86]. First techniques used fibroblast as somatic cells, however 
keratinocytes, lymphocytes, hepatocytes, neurons, or multipotent stem cells are also good 
sources for reprogramming [86]. Regarding availability and reprogramming efficiency, the 
most commonly used somatic cell type is still adult fibroblast [86]. Reprogramming 
methods mainly differ in the route of delivery of pluripotency genes. First protocols used 
retroviral, lentiviral or adenoviral vectors to integrate pluripotency genes into the genome 
of targeted cells. These methods may not be feasible for clinical use, as viral vectors mean 
infection of the cells with viruses and integration of viral genes into the human genome. 
Despite their risks integrating viral vector methods have high reprogramming efficacy. On 
the other hand, use of adenoviral vectors has very low transfection efficiency, although 
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adenoviruses do not integrate into human genome. To overcome feasibility issues, non-
integrating viral methods have been developed, including the Sendai virus as a vector [87]. 
Sendai virus technique provides a safer and more efficient production of hiPSC, using 
RNA-based transfection of pluripotency genes. A special group of DNA-based integration 
technique is called the Sleeping Beauty transposon system [88]. Sleeping Beauty is a non-
viral carrier system of the genetic information that can insert a gene into human 
chromosomes. The future clinical use of Sleeping Beauty transposon system, would be 
much safer than those vector systems that are viral-dependent. Ivics at al. found that the 
chromosomal distribution of Sleeping Beauty transposon insertions is random in the human 
genome. They also proved that insertions could occur at each chromosome. Sleeping 
Beauty transposons could be inserted at specific regions of the human genome, by 
modifying the insertion [89]. Furthermore, the third generation of virus-free/DNA-free 
iPSC was generated by direct delivery of small molecules, proteins and antibodies that 
remodel cellular epigenetic pattern [85, 90, 91]. Transgene-free non-integrating methods 
were developed, e.g. piggyBac system. The piggyBac transposon system enables insertion 
and then directed excision of a naked DNA segment from the genome, thus the constant 
modification of the human genome is avoided [88].  The transfection with a piggyBac 
transposon is completely under control, as the promoter region is induced by an antibiotic 
enhancer (e.g. doxycycline). Finally, modified messenger RNA delivery and microRNA-
based transfection methods also exist. These viral-free/DNA-free, non-integrating methods 
partially eliminated the risk of modifying the human genome. 
Recent studies have investigated the epigenetic effects of reprogramming and genomic 
stability of established hiPSC [92]. The genetic manipulation during hiPSC may be a 
critical issue in clinical scenario. Human iPSC seems to be superior among other 
pluripotent and multipotent stem cell lines, thus assessing and developing the safest and 
most efficient reprogramming method may be a critical issue for future therapeutic use. 
Short summary of reprogramming methods is shown in Figure 4. 
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Figure 4. Advantages and disadvantages of reprogramming methods Figure shows 
main types of reporgramming methods to develop human induced pluripotent stem cells 
from adult, somatic cells. Advantages and disadvantages of main reprogramming methods 
are listed in figure (+ advantage, - disadvantage, original figure from Edit Gara) 
  
DOI:10.14753/SE.2016.1894
25 
 
2.3.  Cardiovascular derivatives of stem cells, preclinical and early clinical results 
 
2.3.1.  Clinical studies investigating endothelial progenitor cells 
 
After characterising EPC, translational research moved toward cardiac 
regeneration. First clinical trials assessed safety and feasibility of their activation in vivo 
and injection after exogenous boost [93-95]. Small clinical trials reported beneficial results 
and improvement in hemodynamic parameters. Injection of EPC into the injured 
myocardium resulted in increased left ventricular ejection fraction (LVEF) and inhibition 
of fibrosis after myocardial infarction [94, 96, 97]. To enhance stent function, anti-CD34 
antibodies were applied onto coronary stents. The bioengineered stents can capture EPC, 
thus enhance endothelisation and defeat late in-stent restenosis. In BOne MarrOw 
Transplant to enhance ST-elevation infarct regeneration (BOOST, NCT00224536) clinical 
trial patients received bone marrow-derived mononuclear cells (hematopoietic precursor). 
The autologous precursor cells were harvested and injected at the same day, after suffering 
ST segment elevation myocardial infarction, with preserved LVEF. The study reported no 
significant adverse event and significant increase in LVEF was found in the treatment 
group, after 6 months follow-up. 
At the Heart and Vascular Centre, Semmelweis University, Budapest, the Cxcr4 
AnTagonism for Cell mobilization and Healing in AMI (CATCH-AMI, NCT01905475) 
trial is investigating effects of endothelial progenitor/stem cells in acute ST segment 
elevation myocardial infarction (STEMI). I am taking part in this trial as a sub-
investigator. This is a phase IIa, double-blind, placebo-controlled, randomised and multi-
centre study of POL6326, a CXCR4 antagonist study drug. The objective of this study is to 
mobilise circulating endothelial progenitor cells by modulating the CXCR4/CXCL12 axis. 
Modulation of CXCR4/CXCL12 pathway results in homing of EPC into the injured 
myocardial tissues. The study drug inhibits CXCR4, thus mobilisation of EPC and their 
homing into the injured myocardium can occur. Enrolled patients received the study drug 
intravenously on day 5 and day 7 after STEMI. The primary end-point of the study is 
increase in LVEF at 4- and 12-month follow-up. The secondary end-point includes detailed 
hemodynamic parameters, mortality parameters and analysis of the level of activated EPC. 
Fluorescence cell sorting method is performed in a core lab, evaluating the exact amount of 
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activated CD31 positive, CD34 positive EPC. Outcome of this and other similar trials will 
reveal if EPC possess efficient regenerative capacity for cardiac repair. Mobilisation, 
characterisation and collection of EPC must improve to use them for regenerative cardiac 
repair. 
 
2.3.2. Clinical results with mesenchymal stem cells for cardiac regeneration 
 
The fate and characteristics of MSC were discussed in details in section 2.2.2. This 
section will introduce the clinical data of MSC treatment in cardiovascular diseases. As 
MSC have good availability and safety profile, most of the current clinical trials were 
performed with these cell types. Unfortunately, some of these clinical trials reported false 
results to enhance beneficial outcome. Comprehensive results of meta-analyses showed 
modest increases in cardiac functional parameters (e.g. LVEF, six-minute walk test 
(6MWT)). However, these significant beneficial effects diminished in longer-term follow 
up [98].  
Major difficulty when comparing clinical results from MSC trials is the diversity in study 
designs. In most studies, intracoronary injections were performed after acute MI, using 
varying numbers of MSC (between 2x10
6
 and 2500x10
6
). However, these clinical trials can 
be described by their procedural heterogeneity, and a lack of standardization [99]. Some 
studies reported beneficial results, like a study from Lunde et al., which showed 
improvement in echocardiography, SPECT and MRI parameters after 6 months follow-up 
[100, 101]. The Reinfusion of Enriched Progenitor Cells And Infarct Remodelling in 
Acute Myocardial Infarction (REPAIR-AMI, NCT00711542) trial recruited a large number 
of patients (240) with acute phase STEMI. This study was a phase II, randomised, placebo 
controlled, and double-blinded one. Patients received autologous intracoronary injections 
of bone-marrow derived MSC (50ml) vs. placebo medium. Detailed coronary artery 
hemodynamics were measured to assess coronary microvascular function. At four months 
after MSC implantation, patients showed significant improvement in LVEF compared to 
placebo (+5.5 vs +3.0%, absolute difference +2.5%).  However, detailed analysis revealed 
that substantial treatment effects of MSC were limited to areas with the greatest damage or 
extent of scarring [102]. 
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Further studies investigated the effects of MSC implantation in stable coronary artery 
diseases. These studies showed improvement in left ventricular function, perfusion and 
relief of angina pectoris [94]. The Transplantation Of Progenitor Cells And Recovery of 
Left Ventricular Function in Patients with non-ischemic Dilatative CardioMyopathy 
(TOPCARE-DCM, NCT00284713) trial studied effects of MSC transplantation in non-
ischemic heart failure. Patients with severe, idiopathic and non-ischemic heart failure 
received autologous implantation of bone marrow-derived progenitor cells into the LAD. 
MSC implantation was found to be safe and feasible in non-ischemic etiology. 
Furthermore, improvement was noted in clinical parameters such as left ventricular 
volume, LVEF and decrease in serum BNP levels. 
In contrast to beneficial study results, some others published minor or no improvement in 
clinical parameters after MSC implantation. A study from Janssens and colleagues found 
no benefit in LVEF, but a significant reduction in infarct size and improved in regional left 
ventricular function [103]. 
Special type of MSC, the endometrial regenerative cells (ERC) is under investigation in 
congestive heart failure. Patients with NYHA III-IV functional status and decreased LVEF 
(<40%) receive ERC implantation via the coronary sinus. The study involves three cohort 
of cell dose: 50-100-200 million. The interim analysis provided beneficial safety results of 
ERC delivery [104]. 
In the recent years meta-analyses published large cohort of results with MSC. These trials 
[105-108] involving altogether 999 patients with acute MI or chronic ischaemic 
cardiomyopathy showed that transplantation of MSC improved LVEF by 5.4%, decreased 
infarct scar size by 5.5% and lowered left ventricular end-systolic volume by 4.8 ml [108]. 
Other meta-analyses [109] indicated that MSC treatment is beneficial; however, the typical 
modest increase in ejection fraction is of uncertain clinical significance. Recent meta-
analysis from Gyöngyösi et al. suggested neutral effects of MSC treatment, especially in 
longer-term follow-up [98]. It was shown that intracoronary or direct intramyocardial 
delivery route may be the most beneficial. Other delivery routes (coronary sinus, systemic 
venous or surgical) have proven less success. The analysed data displayed an overall 0.9-
6.1% improvement in LVEF; nevertheless these improvements diminished in half of the 
trials on the longer term follow-up. By now, arguments are clear that MSC are unable to 
transdifferentiate into cardiomyocytes [110]. Their beneficial effects may derive from 
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immunomodulation, pro-angiogenic, antiapoptotic and anti-fibrotic effects. Table 2. 
summarizes MSC advantages and disadvantages for cardiac regeneration. Preclinical and 
translational studies must improve to enhance MSC use for cardiac regeneration. State-of-
the-art studies suggest utilizing MSC products, which may be responsible for their 
regenerative effects, e.g. transplantation of MSC-derived exosomes and microvesicles only 
[111, 112].  
 
Table 2. Characteristics of mesenchymal stem cells in cardiac regeneration Table 
shows advantages and disadvantages of mesenchymal stem cells concerning cardiac 
regeneration (MSC: mesenchymal stem cells) 
Advantages of MSC Disadvantages of MSC 
Easy to collect, isolate and expand Exact mechanism of action is unclear 
 Low immunogenicity True myocardial differentiation  
is lacking 
Multipotent Large heterogeneity 
Beneficial safety reports from  
previous studies 
Diverse study designs aggravate  
clinical interpretation 
 
While unmodified MSC have shown some promise in cardiac repair, angiogenic and 
myogenic effect of these cells might be enhanced by phenotypic modification. To facilitate 
a standardized performance of MSC used for cardiac repair, a group at Mayo Clinic led by 
André Terzic has used proteomic and genomic analysis to identify critical factors in the 
pathways regulating cardiac differentiation. Their approach has yielded a suite of 
molecules that drive cells in vitro into cardiopoiesis. A company, Cardio3 Biosciences, 
(currently Celyad) completed a clinical study (NCT00810238) to apply this technology for 
the development of the cardiac cell lineage, named: C3BS-CQR-1 (C-Cure®) to treat heart 
failure, reporting a significant improvement of LVEF associated with reduction in LV end-
systolic volume and improvement in the 6MWT [113]. The larger randomized study 
(CHART-1, NCT01768702) is currently recruiting patients with ischemic heart failure. 
This study is running at the Heart and Vascular Centre, Semmelweis University, I am 
currently working as a sub-investigator in the trial. Patients are treated with autologous 
bone-marrow-derived MSC (C3BS-CQR-1) product). MSC are collected from the iliac 
crest via posterior crista biopsy performed by haematologists. A large volume of BM is 
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harvested (65-85ml) in order to collect a sufficient quantity of MSC. Harvested BM is 
shipped to a core laboratory, where MSC are isolated. Cells are treated with a special 
cocktail containing growth factors to enhance development of cardiomyocyte progenitors. 
The differentiation procedure takes up to 7-15 weeks. When the differentiation part is 
completed, autologous cells are shipped back to local hospital sites, where C3BS-CQR-1 is 
injected intra-myocardially via femoral artery catheterisation. C3BS-CQR-1 are expanded 
into cell numbers of 600x10
6
 and injected into 20 sites of the left ventricular wall. The 
primary end-point is set up from a composite involving number of hospitalisations due to 
worsening heart failure, changes in Minnesota living with heart failure questionnaire 
(MLHFQ) (improvement at least ten points) and 6MWT (increase at least 40m), changes in 
LV parameters (15ml absolute change), and LVEF (4% absolute improvement). Secondary 
end-points include efficacy and safety measurements. Safety parameters include the 
number and cause of deaths and hospital re-admissions, the number of cardiac 
transplantations and myocardial infarctions and the number of strokes. Efficacy parameters 
entail time to all-cause mortality, time to worsening of heart failure and time to aborted 
sudden death. After promising results from C-Cure®, CHART-1 gives hope for beneficial 
outcome. 
 
2.3.3.  Clinical studies with cardiac stem cells for cardiac regeneration 
 
Characteristics of cardiac stem cells are discussed in section 2.2.3. Here the 
preclinical results and clinical trials with CSC are discussed. The injection of human 
cardiosphere-derived cells into injured myocardium showed some benefit in animal models 
mainly by improving left ventricular function [114, 115]. The cardiospheres are obtained 
from myocardial biopsy and can give rise to cardiomyocytes, endothelial cells and smooth 
muscle cells. Human cardiospheres exhibit significant proliferation and differentiation 
capacity [114]. Isolated cell populations can be differentiated into spontaneously beating 
aggregates of cardiomyocytes [115]. In mouse model for myocardial infarction epicardium 
derived CSC could restore cardiac function, by reducing dilatation of the heart chambers 
and increasing ejection fraction [116]. 
The CArdiosphere-Derived aUtologous stemCElls to reverse ventricUlar dySfunction 
(CADUCEUS, NCT00893360) trial is a completed phase I safety study, investigating the 
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effects of CSC in ischemic heart failure. During the study procedure by Marban et al. from 
the Johns Hopkins Hospital, small biopsy samples were taken from recruited patients‟ 
myocardium. Later 12.5x 10
6
 or 25x 10
6
 of autologous CSC were injected intracoronary. 
Results reported that CSC inplantation is safe after myocardial infarction [117]. 
Unexpected beneficial results showed in addition to decreased scar size, the increased 
amount of viable myocardium as measured by cardiac MRI [117].  
Therapeutic perspectives of CSC are also investigated in rare and congenital cardiac 
diseases. The Transcoronary Infusion of CArdiac Progenitor Cells in Patients with Single 
Ventricle Physiology (TICAP, NCT01273857) and Cardiac Progenitor Cell Infusion to 
Treat Univentricular Heart disease (PERSEUS, NCT01829750) trials study the effects of 
cardiac progenitor cells in congenital heart diseases. In TICAP, cardiospehere-derived cells 
are implanted intracoronary, one month after Norwood, Glenn or Fontan procedures. 
Patients receive 0.3 million/kg autologous CSC. In phase I designed TICAP trial, safety 
results enhanced the running of phase II PERSEUS trial. 
 
2.3.4. Preclinical and early clinical studies with embryonic stem cells in the 
cardiovascular field  
 
Human ESC have emerged as one of the most promising sources of new cardiac 
cells for transplantation because of their capacity to efficiently undergo directed  
differentiation into genuine cardiomyocytes and supportive endothelial cells. A number of 
groups have successfully isolated cardiomyocytes or cardiac progenitor cells from 
differentiating ESC cultures [118, 119]. These in vitro derived cardiomyocytes have been 
characterized extensively. Structural, electrophysiological and contractility studies 
indicated that ESC-derived cardiomyocytes exhibit a phenotype reminiscent of foetal, 
rather than adult cardiomyocytes. In the animal transplantation models of cardiac disease, 
use of ESC-derived cardiomyocytes has resulted in a significant improvement in 
ventricular function and structure (Table 3.). The cells appear to form gap junctions with 
host cardiac tissue; however, formation of protective fibrotic tissue around the grafts can 
interfere with complete electrophysiological coupling [120]. The beneficial effects in MI 
have been reported one month after transplantation [121].  
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Table 3. Preclinical studies on embryonic stem cell derivatives in myocardial 
infarction models Table shows details of preclinical studies with human embryonic stem 
cells regarding cell number, animal models, timing and follow-up (Table is adapted from 
Kosztin/Gara et al. Stem cell therapy to treat heart failure Elsevier 2015, Reference 
Module in Biomedical Sciences) 
Cell type Number of 
injected cells 
Animal 
model 
Timing Follow-up Ref. 
ESC (cardiac 
committed) 
5x10
7
 sheep 14 days after MI 4 weeks [122] 
hESC-CM 0.03-0.1x10
6
 mouse Day of MI 3-4 weeks [123] 
hESC-CM 10
6
 mouse Day of MI 12 weeks [120] 
hESC-CM 10
7
 rat 4 days after MI 4 weeks [121] 
hESC-CM 10
8
 guinea pig 10 days after MI 4 weeks [124] 
hESC-CM 10
9
  monkey 14 days after MI 3 months [125] 
 
Murry et al. evaluated the effects of human cardiomyocyte implantation in non-human 
primate model of myocardial infarction. In their study design Macaca nemestrina non-
human primates suffered myocardial infarction via balloon inflation in LAD. Two weeks 
later, hESC-derived cardiomyocytes were injected transepicardially into the myocardial 
scar and surrounding tissue. Animals received immunosuppression to avoid rejection of 
human cells. The injected CM cells expressed eGFP construct. This trial was the first to 
prove feasible and successful delivery of large human grafts in MI model. After follow-up 
for 14-84 days electromechanical coupling have been verified. Furthermore, GFP-positive 
human cells were successfully seeded among endothelial cells from host primate, 
suggesting enhancement in angiogenesis. Recently this study has used the largest number 
of injected cells. During the implantation procedure one billion hESC-CM were injected 
into the peri-infarct zone of the hearts. The commendable results postulate for further 
evaluation of post-transplantation expansion, maturation, survival, and long-term effects of 
grafted ESC-derived cardiomyocytes. In Murry‟s large animal model non-fatal, sustained 
ventricular and supraventricular tachyarrhythmias were observed after the implantation of 
cells. These pro-arrhythmogenic effects were not developed in small animal models, 
emphasizing importance of large animal studies [125, 126]. However, these cells have not 
been tested therapeutically since the problems of immunosuppression and the risk of 
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teratomas from residual undifferentiated ESC remain. The latest preclinical data suggest 
that co-transplantation of hESC-derived cardiovascular cells with MSC may enhance the 
beneficial effects of hESC derivatives. MSC may support the engraftment and survival of 
implanted hESC derivatives via anti-inflammatory and immunosuppressive effects [127]. 
The first clinical trials in cardiovascular disease are just launched. Menasche and 
colleagues have differentiated a population of CD15 and Isl1 positive cardiac progenitors 
from hESC. The Transplantation of Human embryonic Stem Cell-derived Progenitors in 
Severe Heart Failure (ESCORT, NCT02057900) phase I trial recruits patients with 
ischaemic heart failure with indication for coronary-artery bypass graft or valvular surgery. 
Eligible patients have NYHA III-IV functional status and decrease LVEF (<35%). During 
the operation a fibrin-based cardiac patch, seeded with CD15/Isl1 double-positive 
cardiopoietic cells, are placed epicardially onto the infarcted area with a pericardial flap 
[32, 128]. 
Table 4. shows the advantages and disadvantages of hESC for regenerative purposes. 
 
Table 4. Advantages and disadvantages of hESC for cell therapy Table lists advantages 
and disadvantages of human embryonic stem cells for cell therapy in heart failure (hESC: 
human embryonic stem cells) 
Advantages of hESC Disadvantages of hESC 
Unlimited availability Ethical and legal considerations 
Off-the-shelf-use Teratoma formation from residual  
stem cells 
Differentiate into functional CM Immunosuppression probably needed 
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2.3.5.  Preclinical results and future challenges with induced pluripotent stem cells  
 
Induced pluripotent stem cell-derivatives promise considerable benefits for disease 
modelling and drug testing in vitro. As hiPSC are generally derived from adult somatic 
cells, new cell lineages may be patient specific. Thus, personalised drug testing and 
therapeutic strategies can be established. Commercially available hiPSC-derived 
cardiovascular cells, especially cardiomyocytes can be used in in vitro assays for testing 
cardiotoxicity, contractile properties, drug-induced early afterdepolarization or QT 
prolongation. First cardiac studies on hiPSC described long QT syndromes and 
catecholaminergic ventricular tachycardias [129-131]. Inherited disorders, like 
arrhythmogenic right ventricular cardiomyopathy or Brugada syndrome were also 
investigated by using hiPSC [132, 133].  
Beside disease modelling in vitro, hiPSC provide platform for cardiovascular tissue 
engineering and cell therapy. A group developed differentiation methods to engineer 
cardiac tissue cell sheet, which contains cardiomyocytes, endothelial cells and pericytes 
[134]. This preclinical study involved implantation of hiPSC-derived cardiac cell sheets 
into rat model of myocardial infarction. The cell sheets were cultured on special thermo-
sensitive polymers, and then the biopolymers were detached without enzymatic digestion. 
This method is promising, as non-enzymatic protocols avoid modification of cell 
phenotype or loss of cell number during enzymatic digestion. Results of this preclinical 
trial are in progress.  
Human iPSC give opportunity to model cardiovascular diseases in vitro, to investigate 
inherited cardiovascular conditions in a dish, to assess cardiovascular drug toxicity and to 
move towards therapeutic options and cardiovascular tisseue engineering; even 
individually. A recent clinical trial, the Individualized Early Risk Assessment for Heart 
Disease (IndivuHeart, NCT02417311) clinical trial is recruiting patients from June 2015. 
The study is aimed to characterise in details phenotype of specific cardiac pathologies in 
engineered heart tissue (EHT) setting, in vitro. EHT enables high-throughput, 
comprehensive studies on hiPSC-CM, in 3D culture platforms [135, 136]. Fourty healthy 
volunteers, ten patients with DCM, ten patients with HOCM and ten patients with HFpEF 
will be recruited. Skin biopsies will be taken and EHT will be developed patient- 
specifically. The study design aims to characterise hiPSC-EHT function in basal and in 
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hemodynamic stress conditions. Furthermore, this study aims to define disease specific 
phenotype in vitro, to study pathophysiology steps of DCM and HOCM in EHT. These 
patient specific EHT constructs provide platform for individualised drug testing both on 
acute applications and long-term drug administrations.  
Tracking cells via cell therapy and studying fate of the transplanted cell is one of the major 
challenges in preclinical trials with hiPSC. At Stanford University, Wu and colleagues 
work on hiPSC-derived cardiomyocytes to provide high scale results regarding prevention 
of donor cell loss during cell therapy [135, 137]. They aimed to establish high-throughput 
imaging techniques to track cells after implantation.  
Advantages and disadvantages of hiPSC for therapeutic purposes are shown in Table 5. 
Advantages may translate into safety, cost-effectiveness and can terminate the ethical 
debates related to harvesting of stem cells from different sources. Immunocompatibility 
issues may be reduced with iPSC derivatives because the beginning cell line (e.g. skin 
fibroblasts) can be obtained patient-specificially. Albeit, the logistics of using them 
therapeutically may not be as simple as hoped [138]. Large-animal models using monkeys, 
dogs and pigs were demonstrated their feasibility and superiority to other pluripotent stem 
cells (ESC), due to low immunological complications with intramyocardial injection of 
autologous cells.  
Efforts are now focused on the development of large hiPSC banks for a variety of diseases. 
Banking these cells, similarly to widespread umbilical cord blood banking, may serve 
public health advantages in the future. Characterizing the human leukocyte antigen (HLA) 
pattern of the banked cells may further enhance their future clinical use. 
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Table 5. Advantages and disadvantages of hiPSC for cell therapy Table lists 
advantages and disadvantages of human induced pluripotent stem cells for cell therapy in 
heart failure (hiPSC: human induced pluripotent stem cells) 
Advantages of hiPSC Disadvantages of hiPSC 
Patient specific therapy Genome instability  
during and after reprogramming 
Patient specific disease modelling Epigenetic modulations 
during reprogramming 
Patient specific drug testing Development of product takes time 
Immunosuppression possibly not needed Teratoma formation from residual cells 
 
 
2.4.  Tissue engineering for cardiovascular repair 
 
In recent years many novel bioengineering methods and perspectives have been 
born, enabling cardiovascular tissue engineering. As cardiovascular diseases are the 
leading cause of death in industrialised countries, replacement of damaged cardiovascular 
tissue is in the focus of research. The number of cadaveric donor organs for cardiac 
transplantation is limited. In case of vascular diseases such as aortic aneurysm and aortic 
dissection, artificial tissue vascular grafts are available, but the number of biological donor 
vascular grafts is also limited. Thus, cardiovascular tissue engineering paves the way for 
novel therapeutic options concerning cardiovascular tissue regeneration. For 
cardiovascular tissue engineering, pluripotent stem cell derivatives and ECM components 
offer promising sources. Beside early clinical trials involving cell therapy in vivo, tissue 
engineering in vitro was also in focus in recent years. In vitro engineered cardiovascular 
tissues are developed for transplantation, to fill the gap between the availability of donor 
organs and their unmet need. 
Tissue engineering requires special cell culture methods in vitro. To develop large number 
of cardiovascular cells, bioreactor systems seem to be ideal for scale-up. For tissue 
engineering purposes at least 10
6
-10
9
 cells (cardiomyocytes, endothelial cells and smooth 
muscle cells) are needed. Simple cell culture methods may be inefficient for such large 
number of cells. Bioreactor systems are capable for developing large capacity cultures with 
or without ECM components. Indeed, bioreactors provide cell culture techniques which 
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enhance maturation of stem cells-derived cardiovascular phenotype (e.g. wall sheer stress 
(WSS)), for the development of arterial endothelial cells) [139]. One of the major 
advantages of bioreactor systems is that cell culture environment is standardised and 
reproducible. In bioreactor systems temperature, the oxygen and carbon-dioxide pressure 
as well as pH are strictly regulated and monitored. Bioreactor systems enable culturing 
cardiovascular cells and ECM components in three dimension systems. 
Beside cardiovascular derivatives of pluripotent stem cells, ECM components determine 
the product of tissue engineering procedure. The ideal ECM for tissue engineering should 
be biocompatible, biodegradable, matching with host environment and non-toxic. It should 
also be able to fulfil functional properties of the engineered tissue (e.g. electromechanical 
coupling and contractile function in case of the myocardium). So far, none of the 
investigated ECM have satisfied all requirements, although many ECM types have been 
established and studied for cardiovascular tissue engineering such as: fibrin [140], collagen 
[141], conductive biopolymers [142] and  hydrogels [143]. The most promising are the 
decellularised biomatrices. Doris Taylor and her group have detailed, in depth research on 
cardiovascular tissue decellularisation. After decellularisation the biografts may be re-
seeded with cardiovascular cells and thus biological cardiovascular tissue could be rebuilt 
[144-147]. This technique holds out for the utopian view of developing a whole new 
human heart. Weymann et al. succeeded to develop a human size whole tissue engineered 
heart in a bioreactor system on decellularised porcine hearts [148]. Decellularised whole 
heart ECM were recellularised with HUVEC and murine neonatal cardiomyocytes. 
Developing every human cell types in the heart (pacemaker cells, atrial cardiomyocytes, 
conductive tissue, ventricular cardiomyocytes, endothelial cells, fibroblasts, pericytes and 
smooth muscle cells) is a major challenge for cell culture and differentiational techniques. 
Valvular tissue engineering is also on the way for regenerative purposes. Synthetic [149] 
and biological [150] ECM are being investigated to provide surface for valvular tissue 
engineering. These matrices are cellularised with endothelial cells from different sources 
[150-152]. Further, state-of-the-art platforms in tissue engineering offer bioprinting of 
biocompatible valvular structures [153]. Biomechanical and thrombogenic properties of 
decellularised valvular matrices are also studied [154]. Valvular tissue engineering may 
have the most benefits in paediatric heart surgery, while engineered biocompatible grafts 
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are able to change shape and grow within the host tissue, during aging of pediatric patiens 
[155-157]. 
Huge efforts have been made to optimise methods for tissue engineering: mechanical and 
electrical stimuli before cell seeding may enhance preconditioning of matrices for cell 
seeding. Furthermore, studying physical patterns (size, porosity, vulnerability, thickness, 
and rupture) enhances optimisation for tissue engineering. Some matrices enable 
encapsulation of growth factors and anti-apoptotic materials to improve cell survival and 
proliferation after seeding [158].  
The groups of Thomas Eschenhangen and W.H. Zimmerman performed in vitro studies on 
EHT. EHT are created from fibrin polymers and hPSC-derived cardiovascular cells 
(cardiomyocytes and fibroblast) [159-162]. EHT provides unique platform for studying 
hPSC-derived cardiomyocytes function in three dimensional cell culture environment. In 
EHT fibrin matrices and cardiovascular cells are anchored to silicone stripes. In EHT 
contractile function of three dimensional structures can be accurately measured [163]. 
Therefore EHT provides platform for cardiovascular drug testing in vitro, even in patient-
specific, personalised manner. Detailed inotropic, lusitropic and chronotropic effects can 
be investigated.  
New preclinical perspectives include cellular transdifferentiation and in vivo gene therapy 
to enhance impaired cardiac function. During transdifferentiation, one mature cell type 
differentiates into another mature cell type. Despite our earlier knowledge on embryonic 
development, transdifferentiation can take place in vivo. After pathologic events 
transdifferentiation may be enhanced or forced to support tissue healing and prevent 
definite injury of cardiovascular cells. Transdifferentiation of fibroblast to cardiomyocytes 
or endothelial cells in vivo would be a cornerstone in prevention or reversion of ventricular 
remodelling. Thus, preclinical research focuses on transdifferentiation mechanisms [164, 
165]. Detailed transcriptome analysis, epigenetic patterns and microRNA profiles are 
investigated to enhance in vivo cardiac regeneration [166, 167]. 
 
  
DOI:10.14753/SE.2016.1894
38 
 
2.5.  Endothelial differentiation and function  
 
Endothelial cells have major role in physiology of the cardiovascular system. Their 
efficient operation is crucial for controlling vessels‟ tone and function of microcirculation. 
This chapter gives a short overview of endothelial physiology. 
By sheathing the inner surface of the vessel wall, endothelial layer connects the flowing 
blood and the vessel tissue, at approximately 350 m
2 
in
 
the human body. It has been proven 
that the endothelium is not only a passive barrier, but it also plays an important role in 
physiological conditions: regulates vessel tone, vascular resistance and fluid flow through 
the capillaries; furthermore regulates metabolic functions [168]. Endothelial dysfunction 
plays a key role in cardiovascular disease, mainly in pathophysiologic steps of 
hypertension, atherosclerosis and diabetes mellitus [169, 170]. Endothelium is capable to 
communicate with smooth muscle cells, via released vasoactive factors [168]. Endothelium 
provides a semipermeable membrane between blood and vessel structure. To fulfil this 
barrier function endothelial cells form a tight monolayer, expressing wide range of cell 
adhesion molecules, like VCAM, ICAM, VE-cadherin, etc. Furthermore, endothelium also 
has a key role in orchestrating blood clotting, by producing mediators and inhibitors that 
regulate platelet activation. In endothelial injury on one hand endothelium enhances blood 
clotting. On the other hand endothelial derivatives inhibit overdrawn blood clotting and 
thrombotic events. Endothelial cells mimic monolayer structure when culturing in vitro, 
thus their morphology show cobblestone pattern [171]. Endothelial vasoactive factors have 
specific receptors on smooth muscle cells, resulting in vasodilation, or in vasoconstriction. 
Endothelial vasoactive agents regulate vessel tone and vascular resistance. Most important 
vasoactive factors in the point of endothelium (ACh, NO - endothelial derived relaxing 
factor (EDRF) and arachidonic acid metabolites) will be discussed.  
Endothelium has the key role in flow induced dilation mechanism in the resistance arteries. 
The vasodilator response given to ACh is ceased after denuding the endothelium [172]. 
The EDRF, mediating smooth muscle relaxation is proven to be NO, is synthetized by 
nitric oxide synthase (NOS), from L-arginine in the vessel wall [173]. The NOS enzymes 
have three isoforms: neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS 
(eNOS). L-arginine is the physiological substrate of the family of NOS enzymes. nNOS 
and eNOS are expressed constitutively whereas iNOS is induced by inflammatory 
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cytokines. The production of NO in vascular beds is regulated by many haemodynamic 
actions such as WSS. Beside its role in flow dependent vasodilation, NO has other 
important functions in the microcirculation. NO is an endogenous modulator of leukocyte 
adherence and modulates platelet and leukocyte activation and adhesion to the vessel wall. 
Upon endothelial damage, subsequent inflammation causes an increase in leukocytes at the 
damaged site. The arachidonic acid-derived prostanoids are produced by COX enzymes. 
The COX enzymes have two isoforms, the COX1 and COX2 isoenzyme. COX1 is 
constitutively expressed in most tissues and produces mainly dilator prostaglandins, like 
PGI2. COX2 isoenzyme is thought to be an inducible enzyme; however it is also expressed 
constitutively. Proinflammatory conditions, inflammation, tissue damage, hypoxemia, 
ischaemic conditions and hyperalgesia induce COX2 enzyme [174]. Another important 
mediator is endothelin-1, which has major role in regulating arterial and venous tone. It has 
been shown as most potent vasoconstrictor agent in the circulation. Endothelin-1 is mostly 
secreted from endothelial cells, although during inflammatory responses it may also be 
produced by other cell types [175].  
Arterial and venous subpopulations of endothelial cells differ not only in their localisation 
but also in their functional properties. In each organ and each level of vascular arch 
endothelial cells have specific functions. The main differences between arterial and venous 
endothelial cells are their functional characteristics. Arterial endothelial cells are 
responsible for regulating vessel tone and setting peripheral vascular resistance in the 
circulation by defining vascular tone of pre-capillary arteries. The vasoactive role is less 
important in venous endothelial cells; however it determines the preload of the left 
ventricle. Furthermore, post-capillary venulas and veins are the site of inflammatory 
reaction where white blood cell rolling, diapedesis and extravasation occur. Thus, venous 
endothelial cells must have different cell adhesion properties than those of arterial 
endothelial cells. Specific sites of the circulation, such as the blood-brain barrier, the renal 
glomeruli and liver sinusoids include endothelial cells with unique properties. It is well-
known that environmental factors (paracrine signals, effects of WSS) may alter arterial and 
venous endothelial fate. Coronary grafts derived from saphenous veins function properly 
after CABG surgery. Recent studies have shown that beside the plasticity of arterial and 
venous fate, developmental potential may be regulated on transcription levels. Arterial and 
venous fate is genetically determined. As arteries and veins have far more different 
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functional role than lymphatic vessels, the development of the first arteries and veins is 
determined genetically; lymphatic vessels develop later from pre-developed veins [176]. 
The major regulatory pathway for arterial development is controlled by VEGF and Notch 
pathways [177]. Notch1, Notch2, Notch5, EphrinB2, DLL4 and Connexin40 are known to 
be regulators for arterial development [176]. EphB4 is responsible for venous 
development, as well as FLT4; the latter is more likely to be a lymphatic marker for 
endothelial phenotype. Other underlying regulatory pathways may also mediate endothelial 
development. A recent study has shown that transcription factor FoxC1 leads to 
development of arterial endothelial cells via upregulation of Notch1 [178]. Furthermore, 
activation of the PI3K/FOXO1A signalling pathway via Notch signals modulates 
endothelial development (Figure 5.). 
 
Figure 5. Differentiation of arterial, venous and lymphatic endothelial cells from 
human pluripotent stem cells Schematic drawing shows differentiational steps, crucial 
growth factors and cytokines responsible for endothelial development in vitro. General 
endothelial and specific arterial, venous and lymphatic markers are listed below each cell 
type. (Original figure is from Edit Gara)  
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2.6.  Phosphatidylinositol 3-kinase (PI3K)-Forkhead box O transcription 
factor 1A (FOXO1A) signalling pathway 
 
Phosphatidylinositol 3-kinase (PI3K), a lipid kinase, has been shown to play an 
important role in regulating cell proliferation, adhesion, DNA repair, senescence and 
stemness [179].  PI3K is highly suited for pharmacologic intervention, which makes PI3K 
pathway one of the most attractive therapeutic targets in cancer and diabetes [179]. The 
effects of PI3K in the therapy of cardiovascular diseases have not been tested yet. The 
members of the Forkhead box O (FOXO) transcription factor family are one of the main 
downstream components of PI3K pathway [180, 181]. FOXO transcription factors are 
critical proteins in the regulation of pluripotency of hESC and in modulation of 
cardiovascular development [182]. FOXO transcription factor family have almost 100 
members, from FOXA to FOXR [183]. FOXO transcription factors are involved in 
response to oxidative stress, cell survival, cell cycle, angiogenesis, energy homeostasis and 
glucose metabolism [184-186]. Specific members of FOXO family have crucial role during 
embryonic development of the cardiovascular system, as Forkhead box O transcription 
factor 1A (FOXO1A)-deficient embryos die around embryonic day 11 because of their 
inefficient vascular and cardiac systems [187]. FOXO1A is also important in regulation of 
endothelial cell fate. Indeed, it has been found that mouse embryonic stem cell-derived 
endothelial cells lacking FOXO1A, are unable to respond to vascular endothelial growth 
factor (VEGF), an important angiogenic growth factor for normal vascular development 
[186]. A better understanding of PI3K-FOXO1A-related signalling in specification of 
human endothelial cells can provide a therapeutic advantage in cell transplantation and 
tissue engineering. Figure 6. shows schematic PI3K/FOXO1A signalling pathway in 
endothelial cells.  
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Figure 6. PI3K/FOXO1A signalling pathway in endothelial cells Schematic figure 
shows regulatory role of PI3K/FOXO1A signalling pathway in endothelial characteristics 
and function (Original figure is from Edit Gara) 
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3. Aims 
 
The aim of this study was to develop and characterise endothelial cells from hESC 
and hiPSC. Gaining detailed information about endothelial differentiation and behaviour in 
vitro and in vivo increases a better understanding of cardiovascular diseases and 
development of new cell products which can be utilised in preclinical studies. 
The specific aims of the project were: 
1. To optimise endothelial differentiation protocols from human pluripotent stem cells. 
2. To characterise endothelial fate in details, particularly arterial and venous 
subpopulations and angiogenesis-related properties. 
3. To investigate the role of PI3K/FOXO1A signalling pathway in endothelial 
differentiation, proliferation, viability and angiogenesis. 
4. To develop three dimensional endothelial cell culture systems for tissue engineering. 
5. To define functional characteristics of endothelial cells, especially anticlotting activity. 
6. To investigate endothelial maturation in vivo and to study effects of in vivo 
environment on endothelial characteristics. 
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4. Materials and methods 
 
4.1.  Human pluripotent stem cell culture 
 
Stem cells were cultured under sterile conditions, using a biosafety cabinet (ESCO 
Class II Type A2, Horsham, USA). Human ESC used in these studies were commercially 
available. All ethical approvals had been acquired for research purposes, before purchase 
(Egészségügyi Tudományos Tanács, Humán Reprodukciós Bizottság, ETT TUKEB). 
Experiments were carried out on WA007 (H7) female hESC line (WiCell Research 
Institute Bank, Madison, USA). hESC culturing, maintenance and passaging followed  
protocols by the supplier. 
Before thawing hESC, 6-well plates (Greiner Bio One, Frickenhausen, Germany) were 
coated with Matrigel (BD Biosciences, San Jose, USA). Matrigel is composed of 
extracellular matrix proteins and derived from Engelbreth-Holm-Swarm 
mouse sarcoma cells [188]. Matrigel is sufficient for supporting maintenance of pluripotent 
stem cells, as H7 stem cells were cultured in feeder-free conditions. 6-well plates were 
coated with the 1:30 dilution of Matrigel and KO-DMEM/F12 media (Life Technologies 
Carlsbad, USA) in ratio 1:1 (1ml/well). During thawing H7 hESC were gently warmed in 
water bath, after removing from liquid nitrogen. To avoid osmotic injury feeder medium 
was added drop wise. Cells were centrifuged (1100 RPM, 5 min), then pellet was re-
suspended and stem cells were plated in Matrigel coated wells in mTeSR1 medium 
(StemCell Technologies, Vancouver, Canada). mTesR1 is a widely used predefined 
medium for human pluripotent stem cells, allowing feeder free conditions. mTeSR1 media 
is made from mTeSR1 basal medium and mTeSR1 supplements, containing wide range of 
factors (rh-bFGF, rh-TGFβ, lithium chloride, pipecolic acid and GABA) and other 
components: anorganic buffers (pH 7.2-7.4), carbohydrates, proteins, vitamins, fatty acids, 
bovine serum albumin; no further addition of proteins or growth factor is required for stem 
cell maintenance [55].  
Human pluripotent stem cell cultures were observed daily by inverted light microscopy. 
Cells were fed daily by complete media change (2ml fresh mTeSR1/each well) and kept in 
37°C, 5% CO2 and 21% O2 conditions. Combined (mechanical and enzymatic) passaging 
procedure was performed every 4-10 days, in 1:4 or 1:6 ratio with dispase (StemCell 
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Technologies) to remove spontaneously differentiated areas of the colonies. Stem cell 
colonies were scraped with mechanical scrapers (Falcon, 353085) or with 5ml pipette tip 
to standard size for further maintenance, freezing and for directed differentiation. 
 
4.2.  Generating human induced pluripotent stem cells 
 
Human iPSC were generated by reprogramming adult somatic fibroblasts to 
pluripotent state (Figure 7.). Skin fibroblasts were derived from the members of our 
research group and were gained from skin biopsies, performed by our plastic surgeon 
collaborator (Dr. Béla Debreczeni). The skin biopsy procedure was carried out under 
sterile conditions and skin samples were immediately suspended in fibroblast medium 
(DMEM (LifeTechnologies) + 20% foetal bovine serum (FBS)). Penicillin-Streptomycin 
(P/S) was added to the medium to prevent contaminations from the normal flora of the 
skin. Skin samples were stacked onto gelatinised flasks. The cells were characterised by 
their phenotypic appearance in culture. Transfection of the fibroblast was performed with 
episomal plasmids: 
-Addgene Plasmid 27077: pCXLE-hOCT3/4-shp53-F 
-Addgene Plasmid 27078: pCXLE-hSK 
-Addgene Plasmid 27080: pCXLE-hULpMXs-KLF4 
-Addgene Plasmid pCXLE-GFP for control 
The transfection procedure was carried out with electroporation (BioRad Gene Pulser 
XCell, Gene Pulser Cuvette cat.no. 1652081). During electroporation procedure cells 
receive electric stimuli in conductive media, resulting in temporary pores of the 
phospholipid layer on the cell membrane, thus transfection reagents can pass through it and 
reach cell nuclei. The transfected cultures were maintained in DMEM + 20% FBS + 
GlutaMax1 (LifeTechnologies), without P/S and in the presence of sodium butyrate 
(Sigma-Aldrich, St. Louis, USA). Changing media every other day was critical, until cells 
have grown 90% in confluence. Before overgrowing, the transfected cells were passaged 
and were seeded onto Matrigel surface and media was changed to mTeSR1 to support 
proliferation of pluripotent cells. After 3 weeks pluripotent colonies were identified in 
culture. Pluripotent stem cell colonies were separated from culture mechanically and plated 
into feeder free conditions. The cell maintenance was the same as for hESC. The 
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fibroblast-derived iPS cells were characterised albeit have not been used in further 
experiments. 
 
 
Figure 7. Generating human induced pluripotent stem cells from adult somatic cells 
Time line diagram shows development of hiPSC. Skin samples were obtained from 
biopsies and stacked on gelatine-coated plates to allow fibroblast outgrowth. Confluent 
fibroblast cultures were transfected with pluripotency genes. After 3 weeks pluripotent 
colonies appeared and were maintained on Matrigel. 
 
4.3.  Characterising pluripotency 
 
The characterisation of pluripotency involved immunecytochemical analysis and 
gene expression analysis. Stem cell cultures were washed with PBS and fixed in 4% para-
formaldehyde (PFA) to perform immunocytochemical staining. Fixation of the clusters in 
PFA lasted for 10 minutes in room temperature. Plates were then washed in PBS three 
times. The permeabilization of the cells were performed with 0.2% Triton X-100 (Sigma-
Aldrich) for 10 minutes and then blocking was performed in 4% FBS in PBS for 1 hour at 
room temperature to avoid non-specific binding of primary antibodies. One of the most 
important pluripotency marker is SSEA4 (stage specific embryonic antigen 4). Stem cell 
clusters were stained with anti-SSEA4 antibody (Abcam, Cambridge, United Kingdom), 
overnight, at 4ºC. Secondary antibody was labelled with Alexa Fluor 488 for one hour. All 
applied antibodies are listed in Table 7. Cells were washed with PBS between incubations. 
Cell nuclei were counterstained with DAPI (Life Technologies). Plates were then stored in 
PBS at 4C prior to imaging, using a Zeiss Observer Z1 microscope. Some wells were 
treated with secondary antibody only in order to determine levels of non-specific 
background staining.  
To identify pluripotent state on gene expression level quantitative real-time polymerase 
chain reaction was performed (qRT-PCR). Pluripotent stem cell samples for RNA isolation 
were stored in Trizol at -80C. Total RNA was isolated from cells with the RNeasy Mini 
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Kit (Qiagen, Venlo, Netherlands), according to manufacturer‟s protocols. In Spin-column 
equal volume of 70% ethanol and sample in Trizol were centrifuged at 10000g for 15 
seconds. RNA was washed with buffers after centrifugation. Total RNA was eluted in 30µl 
of RNase-free water. RNA concentration was measured by micro-volume 
spectrophotometer, NanoDrop 2000c (Thermo Scientific, Waltham, USA). Complimentary-
DNA (cDNA) was synthesized from extracted RNA using the High Capacity cDNA 
Transcription Kit (Life Technologies), according to manufacturer‟s protocols. 10µl of 
Master Mix cocktail (containing reverse transcriptase enzyme and buffers) and 10µl of 
equally attenuated RNA samples were added into Microamp fast reaction tubes and 
incubated for 10 minutes at 25°C – holding; 2 hours at 37°C – cycling then 5 second at 
85°C holding. For quantifying mRNA levels pluripotency marker gene Oct4 qRT-PCR 
was succeeded, using TaqMan
®
 Gene Expression Assay (Applied Biosystems, Life 
Technologies). As housekeeping gene control human glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) endogenous control was used. Table 8. summarizes all assays 
used in PCR experiments. In every case non-templates control (NTC, without cDNA 
template) and non-enzyme control (NEC, without Master Mix were applied to detect 
contamination and non-specific amplification during PCR procedure. PCR was performed 
with real-time PCR instrument (Applied Biosystem, StepOnePlus, Life Technologies or 
Mastercycler® ep realplex, Eppendorf): 2 minutes at 50°C – holding, 20 seconds at 95°C – 
holding, 1 second at 95°C – cycling; 20 second at 60°C – cycling; all together 40 cycles. 
Relative expression was determined by the ∆∆Ct method in which fold increase = 2 -∆∆Ct. 
 
4.4.  Endothelial differentiation 
 
Endothelial differentiation was carried out by using four different protocols. 
Protocols involved either embryoid body formation or monolayer methods. In embryoid 
body method, H7 hESC were maintained in ultra-low attachment plates in order to form 
embryoid bodies (simulating the blastocyst stadium of the developing embryo). In 
monolayer methods, stem cells were maintained on Matrigel in monolayer. The 
differentiation protocols involved both normoxic and hypoxic conditions. To induce 
mesodermal development and endothelial differentiation H7 hESC colonies were seeded 
into EGM2 medium containing EBM2 media (Lonza CC-3156, Basel, Switzerland) and 
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SingleQuot supplements (Lonza CC-4176): growth factors, peptides, hormones and 
antibiotics. Table 6. shows detailed components of EGM2 medium.  
To force differentiation into mesodermal lineage one differentiation protocol included 
extra growth factors and morphogenes in mTeSR1 media (Activin A (R&D systems, 
Minnesota, USA, 10ng/ml), FGF-2 (Peprotech, New Jersey, USA, 10ng/ml), VEGF165 
(R&D systems, 10ng/ml) and BMP4 (R&D systems, 10 ng/ml)). After 24 hours the media 
was removed and replaced with Stemline II complete media (Sigma-Aldrich) containing 
FGF-2, VEGF165 and BMP4 (all at 10ng/ml), differentiating cells were maintained in 
Stemline II medium [171]. EBs were developed by mechanically breaking the hESC 
colonies as described before. EBs were cultured for four days in suspension on ultra-low 
attachment plates either in normoxic or hypoxic conditions. After four days, the EBs were 
seeded onto 0.5% gelatine (Sigma-Aldrich) coated 24-well plates or T25 flasks. At this 
point, one differentiation protocol included further VEGF165 supplementation (1ng/ml 
Peprotech). After 13 days in EGM2 medium, CD31 positive endothelial cells were sorted 
from differentiating culture by fluorescence activated cell sorting method (FACS). Figure 
8. shows endothelial differentiation methods used.  
 
 
Figure 8. Endothelial differentiation methods Time line diagram shows steps of 
endothelial differentiation procedures. H7 hESC colonies were maintained in mTesR1 
medium. Endothelial differentiation began with EB formation or in monolayer. Cells were 
differentiated both in hypoxic and normoxic conditions, with growth factor support. On the 
13th day CD31 positive endothelial cells were sorted with fluorescence activated cell 
sorting method. 
 
DOI:10.14753/SE.2016.1894
49 
 
Table 6. Components of EGM2 medium. Table lists components of EGM2 medium 
 
 
 
4.4.1. Flow cytometry and cell sorting 
 
The hESC-derived differentiating culture was labelled with anti-CD31 antibody, 
conjugated with Alexa Fluor 488 fluorophore (BD BioSciences, Minneapolis, USA) for 
fluorescence activated cell sorting. CD31 is a cell surface endothelial marker protein. 
Labelling the transmembrane domain of CD31 protein allows sorting live cells. To perform 
cell sorting, differentiated cultures were trypsinized (0.25% Trypsin and 0.03% EDTA, 
LifeTechnologies), cell suspension was centrifuged (1100 RPM, 5 min) and the pellets 
were re-suspended in PBS, containing 1% FBS (FACS buffer). FACS buffer was also used 
for diluting antibodies. Cells were counted in hemocytometer before FACS. As controls, 
cells without any labelling and cells labelled with single channel CD31 IgG isotype control 
were used. Isotype control, labelled with Alexa Fluor 488 enabled avoiding false results 
from non-specific binding. Cell sorting was carried out on a FACS Aria II Cell Sorter (BD 
BioSciences). During FACS procedure cells pass through in a small nozzle that is vibrated 
EGM2 BulletKit (EBM2 + SingleQut 
Supplements) 
EBM2 500 ml 
Foetal bovine serum 10 ml 
Human epidermal  
growth factor 
500 µl 
Vascular endothelial  
growth factor  
500 µl 
Human fibroblast  
growth factor B 
500 µl 
Insulin growth factor R3 500 µl 
Hydrocortisone 200 µl 
Heparin 500 µl 
Ascorbic acid 500 µl 
AmphotericinB/Gentamycin  500 µl 
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and produces small drops of the cell-suspension. In the nozzle cells are scanned by a laser 
light and cells gain electrical charge. The laser light excites Alexa Fluor 488 dye which 
emits a colour of light that is detected. By the light information the computer can 
determine which cells to separate and to collect according to their electrical charge. Figure 
9. shows schematic figure of FACS procedure. FACS procedures were performed in 
collaboration with György Várady and Robert Sampson (Membrane Research Group, 
Hungarian Academy of Sciences and National Heart and Lung Institute, Imperial College, 
London, respectively). 
 
 
 
Figure 9. Schematic figure is representing fluorescence activated cell sorting (FACS) 
method During FACS procedure samples are scanned by laser light. The fluorescent, 
CD31 positive cells gain electronic charge, and separated by their electronic property 
(Original figure is from Edit Gara). 
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4.5.  Endothelial cell culture and cell isolation techniques 
 
The CD31 positive endothelial cells were cultured in 0.5% gelatinised T25 or T75 
flasks. Cells were maintained in EGM2 medium and were feeded on every other day. 
Endothelial cells strictly proliferate in monolayer. Passages were needed on every 3-6 days 
according to proliferation rate. To characterise endothelial fate and for further experiments 
passages between 2 and 8 were used. 
In addition to hESC-EC I have also studied hiPSC-derived endothelial cells (hiPSC-EC). 
Human iPSC were available from Osaka University, Japan (ReproCell, Kanagawa, Japan) 
and purchased from Wicell (IMR-90-4); endothelial differentiation steps were same as 
those with hESC. As endothelial control cells, human umbilical vein endothelial cells 
(HUVEC), human aortic endothelial cells (HAEC) and human coronary arterial endothelial 
cells (HCAEC) were used. HUVEC were a gift from the Royal Veterinary College 
London, HAEC and HCAEC were purchased from Lonza, and all were maintained in 
EGM2 medium in gelatinised T25 or T75 flasks. Endothelial cells were used for 
experiments between passages 2 and 6.  
 
4.5.1. Isolation and culture of blood outgrowth endothelial cells 
 
During my academic visit at National Heart and Lung Institute, Imperial College, 
London further human endothelial cell types were available for culture. Blood outgrowth 
endothelial cells (BOEC) were used as control endothelial cells in sheer stress studies to 
characterise endothelial fate. BOEC were isolated in collaboration with Daniel M. Reed at 
the NHLI. All ethical approval from local authorities and informed consent from BOEC 
donors were obtained. BOEC were isolated based on earlier protocols [189, 190].  Briefly, 
peripheral blood mononuclear cells were isolated from blood and expanded on tissue 
culture plates for 22 days in EGM2 medium with 10% FBS on collagen I (Sigma-Aldrich) 
coated plates (5.2 g/cm
2
; BD Biosciences). Typically, endothelial cell colonies emerged 
between 5 and 22 days in culture and were expanded for use in experiments. Cells were 
used between passages 2–8.  
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4.5.2. Isolation of human umbilical vein endothelial cells 
 
During my academic visit in Experimentelle Herzchirurgie, Ruprecht-Karls 
Universität, Heidelberg, I also learnt isolation protocol for HUVEC. Umbilical cords were 
collected in sterile conditions from Obstetrics Department under approval of local ethical 
authorities and after informed consent of the patients. All handling were performed in 
sterile biosafety cabinet. Umbilical cords were cannulated at both sides with 3 side syringe 
taps and were perfused with collagenase B solution (Sigma Aldrich, 2.5mg/ml). Umbilical 
cords were then filled up with collagenase B and incubated for 30 min in 37°C. After 30 
min the umbilical cords were washed out with PBS solution (3 times). All enzyme and 
PBS solution were collected during the washing into 15ml tubes. Then the collected 
samples were centrifuged (1100 RPM, 10 min). The pellets (HUVEC) were re-suspended 
in EGM2 medium and plated onto gelatine coated plates or flask. These isolated HUVEC 
were not used further in my studies.  
 
4.6.  Three-dimensional culture system 
 
Tissue engineering three-dimensional cell culture systems was used to study 
survival, viability and proliferation of pluripotent stem cell-derived endothelial cells (PSC-
EC). The established 3D culture systems were based on bioscaffolds, hESC-EC and 
hiPSC-EC, using in small bioreactor system. 
 
4.6.1. Bioscaffolds 
 
Two types of biological ECM were used to develop 3D cultures: CorMatrix
®
 and 
human aortic pieces. CorMatrix
®
 (CorMatrix ECM Technologies, Roswell, USA) is a 
commercially available ECM for heart and vascular surgery (Figure 10. A). CorMatrix
®
 is 
derived from porcine small intestinal submucosa. During the manufacturing process 
CorMatrix
®
 is decellularised, thus only ECM proteins, such as collagen, elastin and 
adhesion proteins remain. Clinical use of CorMatrix
®
 has already received FDA approval 
for vascular and cardiac repair. A clinical trial has started recently to study its feasibility 
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and safety in tricuspid valve plastic operations (NCT023976689). CorMatrix
®
 samples 
used in our experiments were gift from the company. 
Human aortic samples were used after decellularisation procedure. The aortic wall pieces 
or rings were derived from the Városmajor Biobank (ETT TUKEB 7891/2012/EKU), Heart 
and Vascular Centre and were collected during heart transplantations or other cardiac 
surgeries. The aortic pieces were stored in liquid nitrogen upon harvest and later thawed to 
perform decellularisation procedure. For this, aortic samples were washed in detergent 
solution for 48-72 hours, then in PBS + 1% P/S, until elimination of all detergent 
components (at least 72 hours) (Figure 10. B, C). Decellularisation protocols were adapted 
from collaborators at the Experimentelle Herzchirurgie at Ruprecht-Karls Universität, 
Heidelberg [191-195]. In our experiments decellularised aortic pieces were cut into 300 
µm thin slices with a vibrating microtome system (Campden Instruments, Lafayette, USA 
7000smz). Some slices were homogenized to perform DNA/RNA isolation. 
Decellularisation was confirmed by diminishing all DNA and RNA components, measured 
with Nanodrop. The aortic slices were pre-conditioned in EGM2 media prior to cell 
seeding. 
 
Figure 10. Bioscaffolds for 3D endothelial culture (A) CorMatrix
®
 (B) Decellularisation 
procedure of human aortic samples in detergent solution (C) Decellularised human aortic 
sample 
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4.6.2. Bioreactor system 
 
The small bioreactor system composed of scale-up spinner flask (Corning, Basel, 
Switzerland) (Figure 11.), endothelial growth media, endothelial cells and extracellular 
matrix as a carrier for endothelial growth (50000 endothelial cells/ 0.5cm
2
 matrix). The 
small bioreactor system was kept under physiologic conditions (37°C, 85% humidity, 21% 
O2) for endothelial growth. A magnetic stirrer is integrated into the 
spinner flask which enables shaking together endothelial cells and the 
scaffolds. Bioscaffolds along with hPSC-EC were seeded into the 
spinner flasks. Every other day fresh media was added to the flasks. 
After endothelial re-cellularisation vital imaging (Calcein AM 
(LifeTechnologies) and nuclear imaging with Hoechst-33342 or DAPI 
staining (LifeTechnologies) were performed. Confocal microscope and PCR analysis were 
performed to verify endothelial settlement on biomatrices. Microscope analysis visualised 
endothelial proliferation on the 3D vascular constructs.  
 
4.7.  Endothelial characterisation  
 
4.7.1. Immunocytochemistry 
 
Applied immunocytochemistry were the same as earlier described in section 4.3. To 
label endothelial markers and FOXO1A wide range of immunostainings were used (Table 
7.). Cell nuclei were counterstained with DAPI or Hoechst-33342. All antibodies were 
diluted in 3% bovine serum albumin in PBS. Plates were then stored in PBS, at 4C prior 
to imaging acquired by  Zeiss Observer widefield microscope or Cellomics
®
 VTi HCS 
ArrayScanner (Thermo-Fisher Scientific). Some wells were stained with secondary 
antibody only in order to determine levels of non-specific background intensities. 
Cellomics
®
 ArrayScanner is an automated fluorescence microscope. The system is able to 
automatically scan 96-well or 384-well plates and quantify the spatial and temporal 
distribution of fluorescence. Thus, the system provides detailed, high-throughput data 
about cell size, shape and nuclear size. Furthermore, detailed information can be obtained 
Figure 11.  
Spinner flask 
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about the cytosolic and nuclear fluorescence intensity, which allows quantification for 
translocation of transcription factors [196].  
For live imaging to measure parameters of cell death, supernatant was removed, and 
hESC-EC and HUVEC were stained with TOTO-1 or TMRM (both 1:1000; Life 
Technologies) and Hoechst-33342 (1:200; Life Technologies) for 10 min in EGM2 
medium. Fresh, serum-free medium was added after 1 h incubation. Change in nuclear 
morphology is a hallmark of the final stage in cell death. Nuclear events were recorded as 
additional toxicity readouts regardless of the cell death pathway involved. 
H2O2 was used as a stable reactive oxygen species for induction of cell death in three 
different concentrations (high dose, 900 mM; medium dose, 600 mM; low dose, 300 mM) 
for 12 hours. 
 
4.7.2. Immunohistochemistry 
 
Three weeks after recellularisation procedure 3D vascular constructs were stored in 
formaldehyde upon harvest, to enable paraffin embedding and immunohistochemical 
analysis. Histological sections were analysed with 3D-HisTech software 
(http://3dhistech.com), which enables three dimensional analysis of whole slides in section, 
tissue segmentation and morphometric analysis. Furthermore, the software provides 
surface for human cell detection in surrounding tissue, cell filtering and merging to 
quantify angiogenetic activity. Endothelial cells were stained with anti-human CD31 
antibody. 
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Table 7. Detailed characteristics of all applied antibodies (SSEA-4: stage specific 
embryonic antigen-4, vWF: von Willebrand factor, VE-cadherin: vascular-endothelial 
cadherin, ICC: immune-cytochemistry, M:  mouse, Rb: rabbit, G: goat, D: donkey, N.A. 
not applicable, A546: Alexa Fluor
 
546, DAPI: 4',6-diamidino-2-phenylindole - 
dihydrochloride) 
Target Company/cat.no. Species Isotype Dilution Use 
human  
SSEA-4 
Abcam/16287 M IgG3 1:100 ICC characterising pluripotent 
fate 
human  
TRA-1-60 
Abcam/16288 M IgM 1:100 ICC characterising pluripotent 
fate 
human  
CD31 
Abcam/24590/283
64 
Rb IgG1 1:100 ICC characterising endothelial 
fate 
human  
vWF 
Dako/A0082 Rb IgG1 1:200 ICC characterising endothelial 
fate 
human 
FOXO1A 
Millipore/AB4130 Rb IgG 1:200 ICC characterising FOXO 
pathway 
human 
pFOXO1a 
Cell 
Signalling/94615 
Rb IgG 1:100 ICC characterising FOXO 
pathway 
Ki67 Abcam 15580 Rb IgG 1:100 Endothelial proliferation assay 
Mouse IgG LifeTechnologies/
A10036 
D IgG 1:400 ICC secondary staining A546 
Rabbit IgG LifeTechnologies/
A10040 
D IgG 1:400 ICC secondary staining A546 
Goat IgG LifeTechnologies/
A21085 
R IgG 1:400 ICC secondary staining A546 
DAPI/Hoechst-
33342 
LifeTechnologies/
D21490/ V35118 
N.A. N.A. 1:500 ICC nuclei staining 
Human  
CD31 
BD Pharmigen/ 
558068 
M IgG1 Normalised 
to cell 
number 
FACS, EC sorting 
Mouse IgG1 BD Pharmigen/ 
345815 
M IgG1 1:100 Isotype control for FACS 
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4.7.3. Matrigel tube formation assay 
 
Matrigel tube formation assay was performed on endothelial cells. Matrigel was 
thawed overnight and handled on ice, as it is solidifies over 4°C. 24-well plates were 
coated with Matrigel; endothelial cells were seeded onto the solidified Matrigel. 
Endothelial cultures were imaged after 24h incubation. 
 
4.7.4.  Assessment of endothelial alignment under sheer stress 
 
Endothelial cell alignment under shear stress was determined using in vitro sheer 
stress model [197]. Briefly, cells were grown to confluence in 6-well plates and placed on 
an orbital shaker. The movement of the shaker resulted in a wave of media that transversed 
around the well resulting in a complex pattern of shear stress with directional (laminar) 
shear towards the edge of the well, and non-directional (turbulent) shear at the centre. 
Alignment of cells was visualised by light microscopy. Quantification of cell alignment 
and elongation was carried out using a blind scoring system. Users were blinded to the 
identity of all images, captured at the centre and edge of wells from cells cultured under 
static and shear stress conditions and asked to score alignment (0–4) and elongation (0–4). 
Data were collected from 5 separate scorers. Elongation and alignment were defined and 
explained to blind scorers as follows: „elongation‟ means how stretched the cells appear. A 
cell that looks like a square or cobblestone scores zero. An image with cells that look 
stretched/elongated = 4, with 1, 2 and 3 being intermediate. „Alignment‟ means whether 
the cells are aligned in a similar direction. Remember elongated cells might not be aligned. 
Cells that are strongly aligned in one direction score 4, and cells not aligned and that are 
randomly arranged (regardless of elongation or not) score 0 with 1, 2 and 3 as 
intermediates. For shear stress protocols cells were plated on 6-well plates at a density of 
100000 cells/ well for 48h under static conditions and allowed to reach confluence. Media 
was then replaced with fresh media and cells either exposed to shear stress by placing 
plates on the orbital shaker or incubated under control static culture conditions for a period 
of 4 days. 
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4.7.5. Ac-LDL uptake 
 
Endothelial cells may be identified by their high level metabolism of Ac-LDL. To 
testify endothelial phenotype, cultures were incubated with 1,1'-dioctadecyl-3,3,3',3'-
tetramethyl-indocarbocyanine perchlorate labelled with fluorescent probe (DiI-Ac-LDL, 
LifeTechnologies) for 4 hours, in EGM2 medium at 37°C and imaged by fluorescence 
microscopy. 
 
4.7.6. Gene expression analysis, PCR 
 
Details of PCR methods were mentioned previously in section 4.3. For quantifying 
mRNA levels of arterial, venous, lymphatic and universal endothelial genes qRT-PCR was 
performed, using TaqMan Gene Expression Assay (Applied Biosystems, Life 
Technologies). As housekeeping gene control human glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) endogenous control was used. PCR was performed with real-
time PCR instrument (Applied Biosystem, StepOnePlus, Life Technologies) and the relative 
expression was determined. Relative expression levels of genes of interest were detected. 
Table 8. shows list of studied endothelial genes.  
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Table 8. TaqMan
®
 PCR primers applied in gene expression studies Table is listing 
primers, assays and their purposed use. 
Target Assay Purpose 
Oct4 Hs00999634_gH pluripotency marker 
Notch1 Hs00384907_CE arterial EC marker 
Notch2 Hs00247288_CE arterial EC marker 
EphrinB2 Hs00341124_CE arterial EC marker 
DLL4 Hs00184092_m1 arterial EC marker 
EphB4 Hs01822537_cn venous EC marker 
FLT4 Hs00270779_CE lymphatic/venous EC marker 
VE-Cadherin Hs00170986_m1 EC marker 
NOS3 Hs01574659_m1 EC marker 
CD31/PECAM1 Hs00169777_m1 EC marker 
Angiopoietin-2 Hs01048043_m1 EC marker 
Tie-2/TEK Hs00945142_m1 EC marker 
HIF1a Hs00153153_m hypoxia signalling 
FOXO1A Hs00231106_m1 PI3K signalling 
GAPDH Hs02758991_g1 housekeeping control 
 
 
 
 
4.7.7. Proteome profiling assay 
 
To identify protein production of endothelial cells angiogenesis and hematopoietic 
soluble receptor proteome profiling measurement was carried out on R&D System 
Proteome Profiler Human Angiogenesis Array Kit (ARY007) and Human Soluble 
Receptor Array Kit Hematopoietic Panel (ARY011). Both cell surface supernatant and cell 
lysates were used in these studies. Sample preparation and experimental setup followed the 
manufacturer‟s protocol. Pixel densities on assay membranes were assessed after multiple 
exposures under X-ray, then analysed by ImageJ software. 
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4.7.8. ELISA measurements 
 
Human IL-6, IL-8, Rantes and ET-1 ELISA assays were performed on DuoSet 
ELISA Development System and Quantikine ELISA kits (R&D Systems 
DY206/DY208/DRN00B/DET100). The sample collection, preparation and experimental 
setup followed the manufacturer‟s protocol. IL-6, IL-8 and Rantes production of hESC-
ECs and hiPSC-ECs were compared with HUVEC.  
 
4.8.  Modulation of PI3K/FOXO1A signalling pathway in hESC-EC 
 
4.8.1. Cell treatments with PI3K inhibitor, FOXO1A small interfering RNA, and 
FOXO1A plasmid  
 
Human ESC and hESC-EC were treated with LY294002 (10 μM, 24h; Sigma-
Aldrich) during and after endothelial differentiation. As control, dimethyl sulfoxide 
(DMSO) was used in equal concentration. During endothelial differentiation EGM2 
medium was changed in every 24 hours with LY294002. After sorting CD31 positive 
endothelial cells, hESC-EC were plated onto gelatinised 96-well plates (20000 cells/well) 
and were grown until confluency. Then, cells were treated with LY294002 for 24 hours.  
For FOXO1A small interfering RNA (siRNA) knockdown on differentiating hESC and 
purified hESC-EC cultures, FOXO1A Flexitube siRNA Premix (10 nM, 6 hours and 
24 hours; Qiagen) was performed as per manufacturer's instruction. Scrambled non-
targeting (NT) siRNA (10 nM; Qiagen) was used as negative control. Differentiating hESC 
cultures were retransfected every 48h to maintain effects of siRNA. 
Transfection of hESC-EC with plasmids encoding FOXO1A-eGFP or pmaxGFP (Lonza) 
used as DNA control was carried out by electroporation. Briefly, 10
6
 hESC-EC were 
resuspended in 400 μL of EGM2 medium containing 5 μg plasmid DNA, electroporated on 
a Gene Pulser Xcell Total modular electroporation apparatus (BioRad), using time constant 
program (200 V, 25 ms). Overexpression efficiency was tested by by qRT-PCR and 
experiments were performed 48h later. 
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4.8.2.  Measurement of cell viability 
 
After modulating PI3K/FOXO1A signalling pathway either inhibition or 
overexpression of FOXO1A, cell viability was determined using the commercially 
available AlamarBlue
®
 assay or cell counts. For cell counts, fixed cells were stained with 
DAPI (10µg/ml) and imaged using the Cellomics® VTi HCS Arrayscanner. Data for cell 
counts are expressed as average cells/field based on 49 fields. 
 
4.8.3.  Matrigel tube-formation assay  
 
Matrigel was thawed on ice overnight and 24-well plates were coated with 200 μL 
Matrigel per well and then allowed to solidify at 37°C for 30 min. Control, LY294002, NT, 
or FOXO siRNA-pretreated hESC-EC (50000 cells/well) were plated onto Matrigel and 
cultures were photographed and quantitated after 24 hours of incubation. Cell nuclei were 
stained for Hoechst-33342  at day 0, 1, 2, and 3. The colony formation activity and the 
number of nuclei per colony were assessed by using a Colony Formation BioApplication 
on Cellomics platform. 
 
4.8.4.  PI3K/Akt PCR array 
 
For the PCR array (Human PI3K-AKT Signalling RT2 Profiler PCR Array Kit, 
PAHS-058; Qiagen), cDNA was synthesized from 1 mg of total RNA and then hybridized 
in a 96-well format. PCR array data intensity values were normalized by gene-centered z 
score transformation. A modified z-score threshold of 3.5 was used as criteria defining 
outliers, and these samples were excluded from a rerun of the z-statistics. By calculating 
the gene expression stability measure M, which is the mean pairwise variation for a gene 
from all other tested genes, beta actin (ACTB) and 60S acidic ribosomal protein P13 
(RPL13A) were accepted as being the most stable housekeeping genes in this assay setup. 
Normalized ∆CT values were derived as ∆CT (gene) - ∆CT (averaged geometric mean 
above housekeeping controls). Correlation plots and heatmaps were plotted for all samples 
and technical replicates were averaged. To reveal biologically relevant interactions for 
activated kinases, pathway analysis was performed by Ingenuity Pathways Analysis 
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software (https://analysis.ingenuity.com). Ingenuity Pathways are based on a curated 
database of published literature on gene functions and interactions. As one of the outputs 
Ingenuity identifies hub genes based on high degree of links to other genes in known 
pathways. 
 
4.9.  Antiplatelet functional assay 
 
Assays were set up to characterise antiplatelet function of hPSC-EC. In the 
antiplatelet functional assays levels of Rantes/CCL5 chemokine were measured, which 
reveals level of platelet activation (R&D Systems DRN00B). During the experiments PSC-
EC, control HUVEC cells, engineered 3D constructs and bioscaffolds alone were 
incubated with platelet rich plasma of healthy adults. The levels of Rantes/CCL5 were 
measured from the plasma with ELISA. The experimental groups designed as following: 
1. hESC-EC/hiPSC-EC/HUVEC alone on gelatine + platelet rich plasma 
2. hESC-EC on scaffold / hiPSC-EC on scaffold / HUVEC on scaffold + platelet rich 
plasma 
3. Scaffold alone + platelet rich plasma 
4. Platelet rich plasma alone 
 
Schematic figure shows experimental setup of assays (Figure 12.). Assays were performed 
in 24-well plates. 
 
 
Figure 12. Experimental setup for antiplatelet functional assay 1. Endothelial cells 
alone + platelet rich plasma 2. Endothelial cells on bioscaffolds + platelet rich plasma 3. 
Bioscaffolds alone + platelet rich plasma 4. Platelet rich plasma alone  
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4.9.1. Preparation of platelet rich plasma 
 
The platelet rich plasma (PRP) was derived from healthy adults, members of our 
research group. Blood samples were collected in trisodium-citrate tubes. Tubes were 
shaken gently immediately after blood sampling to enhance dilution of anticoagulant in 
blood. The blood processing was started within 30 minutes of sampling. First, samples 
were centrifuged (1000 RPM, 7 mins, 24°C), supernatant resulted in PRP. Then samples 
were further centrifuged (4000 RPM, 30 min, 15°C), the supernatant resulted platelet poor 
plasma (PPP). In PRP platelets were counted, samples were used in 300G/L concentration 
for antiplatelet functional assay experiment. To dilute PRP, PPP were used. On antiplatelet 
assay, samples were incubated with PRP for 30 mins at 37°C on slow rate stirrer. Finally, 
PRP was collected and centrifuged (4000 RPM, 15 min). ELISA measurements were 
performed from supernatant.  
 
4.10. In vivo experiments 
 
After characterisation of hESC-EC and hiPSC-EC in vitro, in vivo experiments 
were succeeded. The generated hESC-EC, hiPSC-EC and control endothelial HUVEC 
were implanted into athymic nude rats (Crl:NIH-Foxn1
rnu
, Charles River, Sulzfeld, 
Germany), to investigate cell survivecell engraftment, capability of angiogenesis and 
development of vascular structures in vivo. Athymic nude rats are T-cell deficient and 
show depleted cell populations in thymus-dependent areas of peripheral lymphoid organs. 
These animals are suitable for transplantation and carcinogenesis research [198]. Animals 
were housed in microbe free conditions, care and handling fulfilled the Guide for Care and 
Use of Laboratory Animals, published by U.S. National Institutes of Health. Experimental 
protocols were approved by the Animal Use and Care Committee of Semmelweis 
University. Three months old, male, nude rats received general anaesthesia with Ketamine-
Xylazine cocktail (80-100 mg/kg and 5-10mg/kg). During the transplantation procedure 
animals received standard laboratory feed. The generated hESC-EC, hiPSC-EC and 
HUVEC were mixed with Matrigel extracellular matrix (BD Biosciences) to provide 
extracellular matrix components for the transplanted cells. The injected suspension 
consisted of Matrigel (250µl), heparin (64U/ml), recombinant murine basic FGF (80ng/ml, 
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R&D Systems) and EGM2 (70µl). Matrigel and growth factors without cells were used as 
control. The cells were transplanted subcutaneously at four sites of the abdominal region of 
each rat. Two weeks after the implantation animals were harvested after overdosing 
anaesthetics, thus developing respiratory failure. Implantation sites and plugs were 
explanted for immunohistochemistry in order to study development of vascular structures 
from engraftment. Implanted cells were re-isolated from nude rats via enzymatic digestion 
of explanted plugs and sorting CD31 positive human endothelial cells. Further analysis (re-
culturing and gene expression profile) were performed. 
 
4.11. Statistical analysis 
 
Statistical analysis was carried out using GraphPad Prism 5 software. Data are 
presented as the mean ± standard error of mean (SEM). All experiments were carried out in 
least three biological replicates. Data were analysed by Student‟s t-test, paired t-test or 
using one-way ANOVA following Tukey post test detailed in each figure legend. In all 
cases significance was taken as p<0.05.  
 
4.12.  Ethical considerations 
 
The use of hESC clearly raises ethical concerns regarding the destruction of the 
human embryo. EU has accepted that these cells can be used for approved research 
projects provided that they are sourced approximately and with full informed consent.  
Regulations regarding hESC differ in countries. In the USA development of hESC lines 
from IVF embryos is approved. In the EU some countries allow to develop new ESC lines 
(e.g. UK, Finland, Sweden, Netherland and Greece), others ban (e.g. Austria, Denmark, 
France, Ireland, Italy, Portugal and Germany). In Hungary generation of new ESC lines 
from IVF embryos is not authorised, whereas purchasing ESC lines from abroad for 
research purposes is approved. 
Experiments with hESC were carried out with ethical approvals.  H7 hESC line used in the 
Heart and Vascular Centre, Semmelweis University were purchased from WiCell 
Company and were approved for research purposes by Hungarian authorities (ETT TUKEB 
11769-2/2010-1016EHR). All data from the donor have been anonymised before the lines 
reached Heart and Vascular Centre.  
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Generally the approval process on hESC line ensures that each of these cell lines: 1) Were 
created from embryos produced using in vitro fertilization for reproductive purposes and 
were no longer needed for this purpose; 2) The embryos were donated by donor(s) who 
gave voluntary written consent for the embryos to be used for research purposes; and 3) 
The research which resulted in the derivation of these cell lines was conducted under 
review of a local authorities. 
Experiments with induced pluripotent stem cells and with their cardiovascular derivatives 
were performed at the National Heart and Lung Institute, Imperial College, London, 
approved by UK Stem Cell Bank (Ref.No. 20111230).  
Collection and handling of human tissues were performed after informed consents were 
obtained from every patient. The human samples were collected in the Városmajor 
Biobank, Semmelweis University (ETT TUKEB 7891/2012/EKU). 
For in vivo experiments using animals, the Ethical Committee of Hungary for Animal 
Experimentation and the Animal Use and Care Committee of Semmelweis University 
Budapest approved the experimental protocols (Ref.no. 22.1/1098/3/2011). The 
investigation conformed to the Guide for the Care and Use of Laboratory Animals.  
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5.  Results 
 
Results in this section are presented in the following order: characterisation of 
pluripotent stem cells; description of endothelial differentiation; characterisation of 
endothelial properties in vitro in 2D, 3D and in vivo circumstances. Therefore, this section 
will not everywhere follow the order of methods section.  
 
5.1. Characterisation of human pluripotent stem cells 
 
Human ESC (H7, WiCell) and hiPSC (ReproCell, IMR90-4 WiCell) showed 
pluripotent morphology in vitro; they formed colonies on Matrigel matrix surface. Human 
ESC and hiPSC both showed fast proliferation rate. Spontaneous differentiation rarely 
occurred in culture, those cells were discarded by enzymatic digestion or mechanical 
scraping. Figure 13. A shows pluripotent stem cell colonies in vitro. Immunocytochemistry 
analysis proved expression of pluripotency cell surface marker on the hESC. SSEA-4 is a 
cell surface marker on pluripotent stem cells (Figure 13. B). 
 
Figure 13. Phenotype in vitro and immunocytochemical properties of pluripotent stem 
cell colonies (A) Figure shows pluripotent stem cell colonies in culture, captured by 
inverted light microscope (H7 passage 48) (B) Pluripotency marker SSEA-4 is expressed 
on stem cell colony (H7 passage 49) 
 
To assess expression of pluripotent marker genes, qRT-PCR analysis was performed. High 
mRNA levels of OCT4 pluripotency marker gene were found. Expression levels of OCT4 
were normalised to GAPDH housekeeping control. Figure 14. shows OCT4 mRNA levels, 
compared to those in hESC-EB, hESC-EC and HUVEC. OCT4 mRNA levels decreased 
stepwise during differentiation procedure. Significantly lower OCT4 levels were found in 
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hESC-EB, hESC-EC and in control HUVEC than those in undifferentiated cultures. These 
results show that cells loose pluripotency during differentiation. 
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Figure 14. Changes in mRNA levels of embryonic stem cell marker OCT4 Human 
embryonic stem cells (hESC) were differentiated via embryoid body formation (EB) 
towards human embryonic stem cells-derived endothelial cells (hESC-EC). Human 
umbilical vein endothelial cells (HUVEC) were used as control endothelial cells. Data are 
expressed as fold changes vs. mRNA levels in undifferentiated hESC; ***p<0.001 vs. 
hESC, n=3 biological replicates. One-way ANOVA with Tukey post hoc test.  
 
 
5.2.  Reprogramming human adult fibroblasts to pluripotent state 
 
Surgical harvest of human skin tissue was succeeded from healthy adults. Skin 
samples were attached to plastic surface and after one day fibroblasts appeared in culture. 
A semi-confluent fibroblast culture developed one week later, and skin samples were then 
removed. Keratinocytes spontaneously grew at the site of skin tissue on the plastic surface. 
Two weeks after skin harvest, confluent fibroblast cultures were achieved. Figure 15. 
shows steps of fibroblast culturing in vitro. 
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Figure 15. Generation of fibroblast culture from human skin samples (A, B) Human 
skin biopsy samples were attached to plastic surface, fibroblast outgrowth occurred. (C) 
Keratinocytes grew spontaneously from skin tissue. (D) Confluent fibroblast culture was 
achieved after 7-14 days. 
 
 
 
After transfection of human adult fibroblasts eGFP positive cells were seen under 
fluorescent microscope after 2 days (Figure 16. A, B). Transfected fibroblasts were plated 
on Matrigel, colony-like clusters appeared in culture within 2-3 weeks. These colonies 
were recognized and observed daily in inverse light microscope (Figure 16. C, D). 
Colonies were then picked and plated on Matrigel for further expansion and banking. 
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Figure 16. Development of human induced pluripotent stem cells from human adult 
fibroblasts (A, B) Adult fibroblasts express green fluorescent protein after transfection 
procedure. (C, D) Three weeks after transfection pluripotent colonies appeared in culture.  
 
 
Newly generated hiPSC colonies showed expression of pluripotency markers. By confocal 
microscope we have seen expression of pluripotent stem cell markers such as TRA-1-60 
and SSEA-4 (Figure 17.). Around passage 5, hiPSC were banked in liquid nitrogen. 
 
 
Figure 17. Expression of pluripotent cell surface markers on fibroblast-derived 
human induced pluripotent stem cells Pluripotency markers, TRA1-60 and SSEA-4 are 
expressed on human induced pluripotent stem cell colonies (Passage 4). 
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5.3.  Characteristics of human pluripotent stem cells-derived endothelial cells 
 
I have tested four different protocols for endothelial differentiation, as described 
earlier. CD31 positive endothelial cells were sorted from differentiating culture by FACS. 
Differentiation efficiency was calculated from total and CD31 positive cell numbers. 
Among the four endothelial differentiation protocols major, significant differences were 
not found in endothelial differentiation yield. Similarly to earlier protocols, three of those 
tested here were moderately successful in endothelial differentiation. The protocols using 
EB method and VEGF resulted in a generation of ~1-2% endothelial cells. Latest protocol 
includes strong triggers for mesodermal differentiation with an improvement in endothelial 
differentiation yield (~10-15%) [171].  
After differentiation procedure endothelial cells were expanded until passage 5-7. Both 
hESC-EC and hiPSC-EC cultures showed cobblestone pattern in vitro (Figure 18. A). 
Analysis with Cellomics high content microscope revealed that CD31 positive endothelial 
cells were negative for haematopoietic marker CD45. Immunocytochemistry analysis 
showed that hESC-EC and hiPSC-EC are stained positive also for von Willebrand factor 
and CD31 (Figure 18. B, C). Endothelial cultures also showed high intensity of arterial 
endothelial marker DLL4 (Figure 18. D). Human ESC-EC and hiPSC-EC took up ac-LDL, 
and formed capillary-like structures in Matrigel tube formation assay (Figure 19. A, B). 
 
Figure 18. Characterization of pluripotent stem cells-derived endothelial cells (A) 
Human embryonic stem cells-derived endothelial cells (hESC-EC) and human induced 
pluripotent stem cells-derived endothelial cells (hiPSC-EC) formed cobblestone pattern in 
vitro. (B, C, D) Immunocytochemical characterization showed that cells are positive for 
von Willebrand Factor (vWF), CD31 and delta like 4 (DLL4) staining. 
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Figure 19. Acetylated low-density lipoprotein uptake and Matrigel tube formation 
assay on human embryonic stem cells-derived endothelial cells (A) Human embryonic 
stem cells-derived endothelial cells (hESC-EC) and human induced pluripotent stem cells-
derived endothelial cells (hiPSC-EC) took up fluorescence (Alexa Fluor 546) labelled ac-
LDL. (B) hESC-EC and hiPSC-EC formed tube-like structures on Matrigel.  
 
 
Endothelial cells grown from the vasculature (HAEC) and endothelial cells from blood 
progenitors (BOEC) were cobblestone in appearance when grown under static culture 
conditions (Figure 20. A). BOEC and HAEC changed morphology when cultured under 
shear stress using a simple orbital shaker method for four days. Both BOEC and HAEC 
elongated and aligned when exposed to directional shear stress (Figure 20. B edge), but 
remained cobblestoned when exposed to non-directional, turbulent shear stress (Figure 20. 
B centre). Quantification of cell elongation and alignment by blind scoring showed 
statistically significant elongation and alignment of both HAEC and BOEC cultured under 
directional shear stress and that for all conditions hESC-EC did not appear to respond to 
shear stress (Figure 21.).  
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Figure 20. Responses of endothelial cells to shear stress Human embryonic stem cell-
derived endothelial cells (hESC-EC), human aortic endothelial cells (HAEC) and blood 
outgrowth endothelial cells (BOEC) after 4 days cultured under either (A) static conditions 
or (B) under shear stress. Images were taken at the edge of the well, where shear stress is 
unidirectional and cells align; and at the centre of the well, where shear stress had no 
preferred direction. Black arrows on shear plate edge images indicate the direction of shear 
stress. Images are from cells of individual experiments and representative of observations 
made from n= 3–8 experiments.   
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Figure 21. Quantification of elongation and alignment of endothelial cells from 
different sources Human aortic endothelial cells (HAEC), blood outgrowth endothelial 
cells (BOEC) and human embryonic stem cells-derived endothelial cells (hESC-EC) were 
scored for elongation and alignment from images at the centre and edge of the well under 
static and shear stress conditions for 4 days. Scoring (0–4) was carried out by using blind 
scoring system and is the average of five independent scores. Data are mean ± SEM 
(HAEC n = 6–7, BOEC n= 8, hESC-EC n= 6–7) derived from 3 to 8 separate experiments. 
Statistical significance between centre and edge scores for each cell and condition was 
determined by paired t-test (p < 0.05).  
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As assessed by qRT-PCR analysis a robust expression of endothelial and angiogenesis-
related genes was present in hESC-EC and hiPSC-EC. We found a significant increase 
both in arterial (EphrinB2, Notch1, Notch2) (Figure 22. A-C) and venous (EphB4) (Figure 
22. D) endothelial marker genes, as compared to those in undifferentiated (H7 hESC and 
IMR90-4 hiPSC) stem cell populations. However, no significant difference was found 
between arterial and venous endothelial gene expressions. Arterial endothelial marker 
genes had higher expression levels than venous marker genes. Lymphatic endothelial 
marker gene, FLT4 was not detectable in hESC-EC neither in hiPSC-EC populations. 
Marker genes for endothelial cells and angiogenesis, CD31 and vascular-endothelial 
cadherin showed significant increase in hESC-EC and hiPSC-EC as compared to those in 
hPSC (Figure 22. E, F). Comparing hESC-EC and hiPSC-EC showed similar gene 
expression pattern on arterial, venous and general endothelial marker genes.  
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Figure 22. Characteristics of human pluripotent stem cells-derived endothelial cells 
with qRT-PCR Bar graphs show changes in endothelial gene expression levels; (ABC) 
arterial markers EphrinB2, Notch1 and Notch2, (D) venous marker EphB4, (EF) general 
endothelial marker genes: CD31 and vascular-endothelial cadherin were measured. mRNA 
levels are shown as fold changes vs. undifferentiated stem cells. n=3 biological replicates, 
p *<0.05, **<0.01, ***<0.001, One-way ANOVA and Tukey tests. (HCAEC: human 
coronary arterial endothelial cells, hiPSC-EC: human induced pluripotent stem cells-
derived endothelial cells, hESC-EC: human embryonic stem cells-derived endothelial cells, 
HUVEC: human umbilical vein endothelial cells) 
 
 
 
To study arterial endothelial subpopulation on hESC-EC and hiPSC-EC surface intensity 
of arterial endothelial cell surface marker EphrinB2 was further quantitated by automated 
microscopy. After staining hESC-EC, hiPSC-EC and human coronary arterial endothelial 
cells (HCAEC) for EphrinB2, intensity pattern was obtained by measuring fluorescence 
intensity (Figure 23. A). DLL4 is a pivotal marker for arterial endothelial cells and 
regulator in Notch signalling pathway. mRNA levels of DLL4 were significantly higher in 
hESC-EC and hiPSC-EC compared to those in undifferentiated hPSC (Figure 23. B). 
DLL4 levels were correspondingly increased in control endothelial HUVEC cells. 
EphrinB2/EphB4 ratio was analyzed to investigate relationship of EphrinB2/EphB4 
bidirectional signalling pathway. EphrinB2/EphB4 ratio was significantly higher in hESC-
EC and hiPSC-EC than those in HUVEC, suggesting that arterial phenotype is 
respresented in hPSC-EC cultures (Figure 23. C).  
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Figure 23. Characterization of arterial endothelial phenotype on hESC-EC and 
hiPSC-EC in vitro (A) Arterial cell surface marker, Ephrin B2 intensity scale is shown on 
histogram, compared to background control (stained with Alexa Fluor 488) and arterial 
control endothelial cells. (B) Bar diagrams show normalized mRNA levels of DLL4 on 
hESC-EC, hiPSC-EC and HUVEC. DLL4 expression levels are normalized to those in 
hPSC. (C) Bar diagram shows levels of EphrinB2/EphB4 ratio. mRNA levels are 
normalized to those in hPSC. n=3 biological replicates, p**<0.01, p***<0.001 one-way 
ANOVA with Tukey post hoc test. (HCAEC: human coronary arterial endothelial cells, 
hiPSC-EC: human induced pluripotent stem cells-derived endothelial cells, hESC-EC: 
human embryonic stem cells-derived endothelial cells, HUVEC: human umbilical vein 
endothelial cells) 
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Proteome profiling from endothelial cell lysates and supernatants showed the production of 
several angiogenesis-related proteins and cytokines (Figures 24. and 25.). The expression 
and secretion pattern of hESC-EC and hiPSC-EC were similar compared to those in human 
coronary arterial endothelial cells (HCAEC) (Figures 24. A and 25. B). Stem cells-derived 
endothelial cells express and produce factors such as VEGF isoforms, angiopoietin-1, 
angiopoietin-2, angiogenin, activin-A, endoglin, TIMP1, 2 and ADAM 9, 10 (Figure 25. 
A). Heat map analysis of expression levels were compared to those in HCAEC (Figure 25. 
B). Hematopoietic marker proteins (CD23, 49, 56, 58, 59,163) were not detected in hESC-
EC and hiPSC-EC (Figure 24. B). CD105 is expressed both on endothelial and 
hematopoietic progenitors.   
ELISA measurements assessed IL-6, IL-8 and ET-1 secretion in hESC-EC and hiPSC-EC 
and control endothelial HUVEC (Figure 26.). Results revealed significantly higher levels 
of IL-6 and IL-8 proteins in hESC-EC and hiPSC-EC than in undifferentiated stem cells 
(Figure 26.).  Human ESC-EC and hiPSC-EC secreted IL-6 and IL-8 into supernatant in 
similar levels as in HUVEC cultures. Results from ELISA measurement were comparable 
with those in proteome profiling. Both revealed high expression and production of IL-8, 
furthermore both proved higher amount of these inflammatory proteins in hiPSC-EC than 
in hESC-EC. We found significantly lower ET-1 expression in hESC-EC than in control 
HUVEC and HCAEC cells.  
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Figure 24. Proteome profiler analysis of pluripotent stem cells-derived endothelial 
cells (A) Bar graph shows angiogenesis proteome profiler analysis of human embryonic 
stem cells-derived endothelial cells (hESC-EC). Cell lysates of hESC-EC express many 
angiogenesis-related proteins. (B) Bar diagram shows expression of cluster of 
differentiation (CD) soluble receptors assessed by human soluble receptor proteome 
profiler array from cell culture supernatants. Data show expression levels of hESC-EC 
in fold changes compared to those in human coronary artery endothelial cells (HCAEC). 
Statistics are not available as n=2 biological replicates, 4 technical replicates. 
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Figure 25. Human pluripotent stem cells-derived 
endothelial cells produce angiogenesis-related 
proteins, cytokines and soluble receptors (A) 
Proteome profiling array membranes for HCAEC, 
hESC-EC and hiPSC-EC.  (B) Heat map (colours) 
egy kis szinskala felirattal egyszerusiti az eletet 
shows levels of expression of angiogenesis related 
cytokines and soluble receptors in hESC-EC and 
hiPSC-EC. Fold changes (numbers) in expression 
levels are compared to those in human coronary 
arterial endothelial cells (HCAEC). Cell numbers 
were equalized in each experimental run. Statistics 
are not available as n=2 biological replicates, 4 
technical replicates. (HCAEC: human coronary 
arterial endothelial cells, hiPSC-EC: human induced 
pluripotent stem cells-derived endothelial cells, 
hESC-EC: human embryonic stem cells-derived 
endothelial cells, HUVEC: human umbilical vein 
endothelial cells) 
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Figure 26. Stem cell-derived endothelial cells produce IL-6, IL-8 and ET-1 in vitro 
Bar graphs show production of interleukin-6 (IL-6), interleukin-8 (IL-8) and Endothelin-1 
(ET-1) proteins. IL-6, IL-8 and ET-1 production were measured from the supernatant of 
5x10
5
 cells and normalized to those in hPSC. n= 6, p***<0. 001 from n=3 biological 
replicates, One-way ANOVA and Tukey post hoc test (BOEC: blood outgrowth 
endothelial cells, HAEC: human aortic endothelial cells, hiPSC-EC: human induced 
pluripotent stem cells-derived endothelial cells, hESC-EC: human embryonic stem cells-
derived endothelial cells, HUVEC: human umbilical vein endothelial cells) 
 
 
5.4.  Role of differentiation conditions on endothelial marker genes and on arterial 
and venous endothelial subpopulations 
 
Although differentiation conditions did not influence significantly the yield of 
generated CD31 positive endothelial cells, expression of general, arterial and venous 
endothelial marker genes were clearly modulated by cell culture conditions. 
Further in-depth analysis of arterial and venous endothelial marker genes were carried out 
during endothelial differentiation protocols. Levels of arterial (EphrinB2, Notch1 and 
Notch2) and venous (EphB4) marker genes were measured during differentiation steps. In 
all differentiation protocols almost stepwise increases were observed in mRNA levels of 
endothelial marker genes via differentiation. No significant differences were found 
between endothelial differentiation protocols in terms of expression of arterial and venous 
markers. However EB/normoxia method resulted in the highest levels of these markers. 
Figure 27. shows levels of arterial and venous marker genes via differentiation in EB 
normoxia (Figure 27. A), EB hypoxia (Figure 27. B) and monolayer+VEGF (Figure 27. C) 
methods.  
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Figure 27. Differentiation conditions influence expression of arterial and venous 
endothelial marker genes during endothelial differentiation Line graphs show changes 
in mRNA levels of arterial (EphrinB2, Notch1, Notch2) and venous (EphB4) endothelial 
marker genes via differentiation (time points: undifferentiated hESC (H7), day 5, day 13 
and after FACS). (A) Embryoid body in normoxia method (B) Embryoid body in hypoxia 
method (C) monolayer+VEGF method. n=3 biological replicates, p *<0.05, **<0.01, 
***<0.001 One way ANOVA, Tukey post hoc test. 
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5.5.  Role of PI3K/Akt/FOXO1A pathway on endothelial differentiation 
 
Next we aimed to study role of PI3K/FOXO1A signalling pathway on endothelial 
development from hESC. As embryoid body in normoxia differentiation protocol resulted 
in highest levels of endothelial marker gene expressions we modulated PI3K/FOXO1A 
pathway on this differentiation protocol. To investigate the changes of genes related to 
PI3K pathway during endothelial differentiation of hESC, we analysed the expressions of 
main PI3K genes using a PCR array. Undifferentiated, differentiating hESC-EB and sorted 
CD31 positive hESC-EC showed different expression levels of most genes tested in this 
pathway (Figure 28.). Undifferentiated hESC expressed high mRNA levels of FOXO1A 
transcription factor; this critical downstream element of PI3K pathway was strongly down-
regulated during differentiation. When compared to HUVEC, we found matching 
expression levels of most of the PI3K pathway elements in hESC-EC (Figure 29.). 
However, expression of FOXO1A was higher in HUVEC as compared to those in hESC-
EC, suggesting that PI3K/FOXO1A may have distinct modulatory role in these endothelial 
cells (Figure 29. A). We also found that mRNA levels of PI3K-partners such as tyrosine-
protein kinase BTK and CD14 were higher, whereas PIK3R1 and PDGFRA were lower in 
hESC-EC than those in HUVEC. To infer gene networks from expression profile of hESC-
EC, Ingenuity pathway network analysis was performed. It suggested that FOXO1A 
expression is specifically linked to an indispensable cluster of angiogenesis- and vascular 
remodelling-related genes, including VEGF2 as well as PDK1 (pyruvate dehydrogenase 
kinase isoenzyme-1), cdc42, and PRKCB1 (Figure 29. B). Furthermore, analysis suggests 
that VEGF may signal through PTEN (phosphatase and tensin homolog) /PDGFRA 
pathway and modulate FOXO1A. 
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Figure 28. PI3K/FOXO1A signalling-related gene expression during hESC 
differentiation Heat map with agglomerative clustering shows changes in mRNA levels of 
PI3K/FOXO elements during different steps of endothelial differentiation: undifferentiated 
human embryonic stem cells (hESC), embryoid bodies (EB), human embryonic stem cells-
derived endothelial cells (hESC-EC). Heat map shows modified z-score compared to 
expression levels in control endothelial human umbilical vein endothelial cells (HUVEC). 
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Figure 29. PI3K/FOXO1A signalling-related gene expression during hESC 
differentiation (A) Bar graphs show differences in essential elements of PI3K/FOXO1A 
signalling pathway in HUVEC vs. those in hESC-EC. Data are expressed as fold changes 
vs. mRNA levels in undifferentiated hESC; mean±SEM. *p<0.05, **p<0.01, ***p<0.01, 
from 3 biological replicates. (B) Schematic diagram of Ingenuity Pathway Analysis-
mapped mechanistic interactions of various angiogenic modulator elements. Arrows 
between nodes represent direct (solid lines) and indirect (dashed lines) interactions 
between molecules as supported by information in the Ingenuity pathway knowledge base. 
hESC: human embryonic stem cells, EB: embryoid bodies, hESC-EC: human embryonic 
stem cells-derived endothelial cells, HUVEC: human umbilical vein endothelial cells, 
ITGB1: integrin beta-1, PRKCA: protein kinase C alpha, PRKCZ: protein kinase C zeta, 
PDGFRA: platelet-derived growth factor receptor alpha, PTEN: phosphatase and tensin 
homolog, PRKCB: protein kinase C beta, PIK3R2: phosphoinositide-3-kinase regulatory 
subunit 2 beta, SHC1: Src homology 2 domain containing transforming protein 1 
 
 
 
Use of PI3K inhibitor/FOXO1A activator LY294002 increased the percentage of newly 
formed CD31 positive hESC-EC in the presence of EGM2 medium, containing endothelial 
growth factors (LY294002 0.62±0.04% vs. control differentiating hESC culture 
0.24±0.1%). Silencing of FOXO1A by siRNA during differentiation had no influence on 
the percentage of CD31 positive cells (Figure 30.). 
 
 
 
 
 
 
 
 
 
 
Figure 30. PI3K/FOXO1A signalling pathway modulates endothelial differentiation 
yield from undifferentiated human embryonic stem cells Bar graph shows CD31
 
positive hESC-EC population in the presence of FOXO1A siRNA or LY294002 (10μM). 
*p<0.05, ***p<0.001 vs. control group (DMSO for LY394002 control), 3 biological 
replicates. One-way ANOVA and Tukey post hoc test. hESC-EC: human embryonic stem 
cells-derived endothelial cells, NT siRNA: non-targeted siRNA, DMSO: dimethyl-
sulfoxide   
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5.6.  Modulation of PI3K/FOXO1A signalling pathway in sorted hESC-EC 
 
To test the effects of PI3K/FOXO1A modulation in hESC-EC, we treated cells with 
LY294002 or FOXO1A siRNA (Figure 31. A, B). Nuclear translocation and mRNA levels 
of FOXO1A were markedly increased in hESC-EC in response to LY294002 (Figure 31. 
C, D). In contrast, silencing of FOXO1A with siRNA decreased both mRNA and nuclear 
translocation levels of FOXO1A as early as after 6 hours treatment in hESC-EC (Figure 
31. E, F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Modulation of FOXO1A expression and nuclear intensities (A) Changes of 
FOXO1A mRNA levels after treatment with the PI3K inhibitor/FOXO1A activator 
LY294002 (10μM) or (B) FOXO1A silencing using siRNA in differentiating hESC. (C) 
Changes of FOXO1A nuclear intensity and (D) mRNA levels in hESC-EC after treatment 
with the PI3K inhibitor/FOXO1A activator LY294002 (24 h). (E) Silencing of FOXO1A 
using siRNA caused decreased level of nuclear intensity or (F) FOXO1A mRNA 
levels.**p<0.01, ***p<0.001 vs. control, n=4 One-way ANOVA and Tukey post hoc test.  
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5.7.  Differentiation conditions and PI3K/FOXO1A pathway modulates angiogenic 
activity of hESC-EC  
 
Main angiogenic regulator angiopoietin-2 expression was modulated by endothelial 
differentiation conditions such as embryoid body formation or monolayer technique 
(Figure 32.). Normoxia (21% O2) with embryoid body method was the most effective to 
increase angiopoietin-2 levels. Significantly higher levels of angiopoietin-2 were achieved 
via embryoid body technique. Embryoid body differentiation method in hypoxic condition 
had stronger induction on angiopoietin-2 levels than monolayer method (Figure 32. A). 
These results suggest that embryoid body method is more efficient to generate mature 
endothelial cells. To endorse hypoxic model, HIF1α levels were measured. HIF1α mRNA 
levels were significantly increased in hypoxic differentiation protocol, validating effective 
hypoxia generation in culture (Figure 32. B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32.  Hypoxia modulates expression of angiopoietin-2 and HIF1α (A) Bar graphs 
show changes in angiopoietin-2 levels modulated by differentiation conditions. mRNA 
levels are normalized to those in H7 hESC. (B) Bar graphs show changes in HIF1α levels 
modulated by normoxia and hypoxia. mRNA levels are normalized to those in H7 hESC. 
Cell numbers were equalized at each time point. n=3 biological replicates, p *<0.05, 
**<0.01, ***<0.001, One-way ANOVA and Tukey post hoc test. 
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As embryoid body formation method in normoxia resulted in highest levels of 
angiogenesis marker genes, further analyses were done on this endothelial differentiation 
method. Levels of endothelial marker CD31, angiogenesis marker Angiopoietin-2 and its 
receptor Tie-2 were characterised. Results proved that mRNA levels of CD31, 
Angiopoietin-2 and Tie-2 are increasing gradually during differentiation (Figure 33.). 
Expression levels on hESC-EC were comparable with those on control HUVEC. 
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Figure 33. qRT-PCR characteristics of human pluripotent stem cells-derived 
endothelial cells differentiated via embryoid body, normoxia method Bar graphs show 
changes in gene expression levels of CD31, Angiopoietin-2 and Tie-2 levels. mRNA levels 
in EB, hESC-EC and HUVEC are shown as fold changes vs. undifferentiated stem cells. 
n=3 biological replicates, p *<0.05, **<0.01, ***<0.001, one-way ANOVA with Tukey 
post hoc test. hESC: human embryonic stem cells, EB embryoid bodies, hESC-EC: human 
embryonic stem cells-derived endothelial cells, HUVEC: human umbilical vein endothelial 
cells  
 
Next we targeted PI3K/FOXO1A pathway to directly assess its role in endothelial 
differentiation. Administration of LY294002 during differentiation increased mRNA levels 
of CD31 and angiopoietin-2 in differentiating hESC (Figure 34. A, C). Cells treated with 
FOXO siRNA showed however decreasing tendency in mRNA levels of CD31 (p=0.07) 
and lower mRNA levels of angiopoietin-2 (p<0.001) as compared with non-targeting 
siRNA group (Figure 34. B, D). Treatment with FOXO siRNA resulted in increased 
mRNA levels of Tie-2 and VE-Cadherin (Figure 34. E, F).  
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Figure 34. PI3K/FOXO1A signalling modulates endothelial differentiation of hESC 
(A-F) Bar graphs show mRNA levels of CD31, angiopoietin-2, Tie-2 and vascular-
endothelial cadherin in differentiating hESC after (A, C) LY294002 treatment  and (B, D, 
E, F) FOXO1A small interfering (si) RNA treatment. *p<0.05, **p<0.01 vs. control group, 
n=3 biological replicates. One-way ANOVA and Tukey post-hoc test. 
 
To test the effects of PI3K/FOXO1A modulation in hESC-EC, we treated cells with 
LY294002 or FOXO1A siRNA. The mRNA levels of CD31 and angiopoietin-2 were 
increased in response to LY294002 in hESC-EC (Figure 35. A, B); on the other hand, 
FOXO siRNA resulted in lower mRNA levels of angiopoietin-2 (Figure 35. D, E). The 
mRNA levels of the angiopoietin-2 receptor, Tie-2 showed reverse regulation as 
angiopoietin-2 expression. Treatment with LY294002 decreased the mRNA levels of Tie-
2, whilst treatment with FOXO siRNA resulted in increased mRNA levels of Tie-2 (Figure 
35. C, F). 
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Figure 35. PI3K/FOXO1A signalling modulates angiogenesis-related gene expression 
activity of hESC-derived endothelial cells Bar graphs show changes in gene expression 
levels of CD31, angiopoietin-2, Tie-2 in differentiated hESC-EC in response to 24 hours 
treatment with (ABC) LY294002 or (DEF) FOXO1A small interfering (si) RNA. n=3 
biological replicates. One-way ANOVA and Tukey post-hoc test 
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In vitro tube formation assay revealed that LY294002 inhibits hESC-EC migration and 
formation of tubes (Figure 36. A-D). On the other hand, silencing of FOXO1A by siRNA 
markedly increased in vitro tube formation activity of hESC-EC as shown by total tube 
length and node count (p<0.001, Figure 36. A, E, F, G).  
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Figure 36. PI3K/FOXO1A pathway modulates in vitro tube formation of hESC-EC 
(A) Representative Matrigel tube formation images of hESC-EC pre-treated with 
LY294002 or FOXO1A small interfering (si) RNA. Cells were stained with vital dye 
TMRM (red). Bar graph show average and total tube lengths and number of formed nodes 
after (BCD) LY294002, (FGI) FOXO1A or non-targeting scrambled (NT) small interfering 
(si) RNA.***p<0.001 vs. control, n=3 biological replicates. One-way ANOVA and Tukey 
post test. 
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5.8. Effects of PI3K/FOXO1A pathway on arterial, venous and general endothelial 
gene expressions 
 
To assess the modulatory effects of PI3K/FOXO1A signalling in arterial and 
venous endothelial subpopulations hESC-EC and hiPSC-EC were overexpressed with 
FOXO1A. After FOXO1A plasmid overexpression universal endothelial marker genes and 
special arterial and venous endothelial marker genes were studied.  qRT-PCR revealed that 
FOXO1A overexpression downregulates expression of all endothelial genes investigated. 
Figure 37. shows that CD31, angiopoietin-2 and VE-Cadherin levels were significantly 
decreased. Arterial and venous marker genes were parallel decreased. FOXO1A 
overexpression had corresponding effects on hESC-EC and hiPSC-EC (Figure 37. C). 
EphrinB2/EphB4 ratio was calculated after FOXO1A overexpression, result shows huge 
decrease to those in control hESC-EC, hiPSC-EC (Figure 37. D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Effects of PI3K/FOXO1A modulation on endothelial marker genes in 
hESC-EC and hiPSC-EC (AB) Bar graphs show changes of expression of arterial 
(Notch1, Notch2, EphrinB2), venous (EphB4) and universal endothelial marker genes 
(CD31, angiopoietin-2 and VE-cadherin). (C) FOXO1A mRNA levels were increased via 
FOXO1A-overexpression (D) EphrinB2/EphB4 ratio after FOXO1A overexpression and in 
control human embryonic stem cells-derived endothelial cells (hESC-EC) and human 
induced pluripotent stem cells-derived endothelial cells (hiPSC-EC). ***p<0.001 vs 
control, n=3 biological replicates. One-way ANOVA and Tukey post hoc test.  
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5.9. Effects of PI3K/FOXO1A pathway on hESC-EC proliferation 
 
Proliferative activity of sorted hESC-EC cultures were assessed by Ki67 marker 
and colony formation. Percentage of Ki67
+
 cells and colony formation activity after 3 days 
were significantly decreased in response to LY294002 (Figure 38. B, C); in contrast, 
further downregulation of FOXO1A expression by siRNA treatment resulted in a modest 
increase in the ratio of Ki67
+
 cells (p<0.05) with no effect on cell number (Figure 38. A, B, 
D).  
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Figure 38. PI3K/FOXO1A pathway modulates proliferative activity of hESC-EC (A) 
Representative picture of Ki67
+
 cells in hESC-EC population. (B) Changes in proliferation 
rate of the human embryonic stem cells-derived endothelial cell (hESC-EC) population 
(Ki67
+
 cells) after 24 hours and in colony formation activity (CD) in response to 
LY294002 or FOXO1A small interfering (si) RNA treatments. (EF) Changes in 
proliferation rate of the hESC-EC population (Ki67
+
 cells). Data are expressed as fold 
changes vs. percentage of Ki67
+
 cells in control hESC-EC group, mean ± SEM. Fold 
changes in mRNA levels are shown vs. human embryonic stem cells (hESC). *p<0.05, 
***p<0.001 vs. control, n=3 biological replicates. One-way ANOVA and Tukey post hoc 
test. 
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5.10.  Effects of  PI3K/FOXO1A pathway on hESC-EC viability 
 
Next, role of PI3K/FOXO1A pathway on viability and cell survival of hESC-EC 
was tested. As assessed by high content microscopy, oxidative stress induced by H2O2 
activated FOXO1A as shown by its increased nuclear density (Figure 39.). Using H2O2 as a 
danger signal caused necrosis and nuclear remodelling (expressed as decreased nuclear 
size) in a dose-dependent manner in hESC-EC (Figure 39. C, D). Silencing of FOXO1A by 
siRNA had no effect on levels of necrosis marker TOTO1 or nuclear remodelling in hESC-
EC (Figure 39. B-D). Pre-treatment with LY294002 increased the pro-necrotic effects of 
H2O2 (at a dose of 600 µM, P<0.001) in hESC-EC (Figure 39. C).  
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Figure 39. Cell death of hESC-derived endothelial cells is modulated by 
PI3K/FOXO1A signalling pathways H2O2 was used in different concentrations (300, 
600, 900 μM) to induce oxidative stress. LY294002 (10μM, 24h) and FOXO1A-targeting 
small interfering (si)RNA (24h) were used to modulate FOXO1A activity. (A) 
Representative immunocytochemistry images of FOXO1A intensity during cell death 
experiments of human embryonic stem cells-derived endothelial cells (hESC-EC). Human 
ESC-EC were stained with anti-FOXO1A antibody and nuclei stained with Hoechst-
33342. (B) Bar graph shows changes in FOXO1A nuclear translocation in hESC-EC pre-
treated with LY294002 and FOXO1A siRNA after challenging with H2O2. (C) Bar graph 
shows changes in necrotic rate measured by TOTO-1 intensity of hESC-EC. (D) Changes 
in nuclear remodelling is calculated by measuring Hoechst-33342 positive nuclear size of 
hESC-EC. ***p<0.001 vs control, n=3 biological replicates. One-way ANOVA and Tukey 
post hoc test. 
 
 
 
5.11. Modulation of endothelial gene expressions and anticlotting function in 3D 
cultures 
 
Culturing hESC-EC and hiPSC-EC in 3D culture conditions aimed for scaling up 
vascular tissue engineering. Human ESC-EC, hiPSC-EC or HUVEC were cultured and 
expanded in spinner flasks and seeded on Cormatrix and decellularised human aortic 
slices. After 10 days in spinner flask, cultured endothelial cells seeded on bioscaffolds, 
proven by vital dyes (Figure 40. A). 3D Histech imaging showed that CD31 positive 
endothelial cells form closely monolayer structure on biomatrices (Figure 40. B). 
Anticlotting function of hESC-EC, hiPSC-EC and HUVEC was investigated by Rantes 
chemokine ELISA assay. Secretion of Rantes chemokine was measured in platelet rich 
plasma after incubating 3D vascular structures. Rantes is secreted from activated platelets, 
thus its level refers to clotting status in platelet rich plasma. Results showed similar 
antiplatelet activity in hESC-EC, hiPSC-EC and HUVEC. According to similar results in 
control and „matrix alone‟ samples, the matrix itself was not thrombogenic (Figure 40. C-
E). Endothelial cells decreased secretion of Rantes, suggesting lower platelet activation. 
The anticlotting effects of endothelial cells were stronger when they were cultured in 3D 
cultures (Figure 40. C-H). Results were comparable on two types of biomatrices, 
suggesting that hESC-EC and hiPSC-EC would possess stable phenotype on different 
biomatrices (i.e. variability of human ECM in vasculature). Anticlotting effects of hESC-
EC and hiPSC-EC were similar as in HUVEC (Figure 40. C-H). 
 
H2O2 
DOI:10.14753/SE.2016.1894
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. 3D culture and anticlotting effects of hESC-EC, hiPSC-EC and HUVEC 
Recellularised biomatrices were seeded with hESC-EC and hiPSC-EC (A) Calcein AM 
live cell imaging, 20X. (B) 3D Histech imaging analyses of CD31 positive hESC-EC and 
hiPSC-EC on decelluraised aortic slices. Bar graphs show changes in Rantes chemokine 
levels, measured from platelet rich plasma after incubation 3D vascular constructs. (CF) 
hESC-EC, (DG) hiPSC-EC and (EH) HUVEC showed similar anticlotting activity on 
(CDE) Cormatrix and (FGH) decellularised human aortic samples. n=3 biological 
replicates, One-way ANOVA with Tukey post test, hESC-EC: human embryonic stem 
cells-derived endothelial cells, hiPSC-EC: human induced pluripotent stem cells-derived 
endothelial cells, HUVEC: human umbilical vein endothelial cells   
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5.12.  Transplantation of hESC-EC, hiPSC-EC and HUVEC in vivo 
 
To test the viability and maturation of hESC-EC with low FOXO1A levels also in 
vivo, cells were transplanted into athymic nude rats. Human ESC-EC, hiPSC-EC and 
control endothelial HUVEC showed engraftment. After 21 days conditioning of cells, all 
general endothelial marker genes as well as arterial and venous marker genes were 
increased. General endothelial markers, Angiopoietin-2, Tie-2, CD31 and NOS3 mRNA 
levels were markedly increased in hESC-EC similar to those in control HUVEC (Figure 
41. B-E). However, hESC-EC retain their low FOXO1A expression levels during the 
incubation period, whereas FOXO1A mRNA levels are further increased in HUVEC 
(Figure 41. A). Arterial (EphrinB2, Notch1 and Notch2) and venous (EphB4) endothelial 
marker mRNA levels were increased significantly in all studied endothelial cells (hESC-
EC, hiPSC-EC and HUVEC) after engraftment (Figure 42.). 
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Figure 41. In vivo conditioning modulates mRNA levels of FOXO1A and universal 
endothelial marker genes Grouped bar graphs show (A) FOXO1A, (B) Angiopoietin-2, 
(C) Tie-2, (D) CD31 and (E) NOS3 endothelial marker mRNA levels before and after in 
vivo conditioning of hESC-EC, hiPSC-EC and HUVEC in Matrigel plugs, transplanted 
into athymic nude rats. (mRNA levels are normalised to those in preimplanted samples for 
each gene) n=12 from 3 biological replicates. * p<0.05 ** p <0.01 *** p<0.001 One-way 
ANOVA and Tukey post hoc test, hESC-EC: human embryonic stem cells-derived 
endothelial cells, hiPSC-EC: human induced pluripotent stem cells-derived endothelial 
cells, HUVEC: human umbilical vein endothelial cells  
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Figure 42. In vivo conditioning modulates mRNA levels of arterial and venous 
endothelial marker genes Grouped bar graphs show (ABC) arterial and (D) venous 
endothelial marker mRNA levels before and after in vivo conditioning of hESC-EC and 
hiPSC-EC in Matrigel plugs, transplanted into athymic nude rats. (mRNA levels are 
normalised to those in preimplanted samples for each gene) n=12 from 3 biological 
replicates. * p<0.05 ** p <0.01 *** p<0.001 One-way ANOVA and Tukey post hoc test, 
hESC-EC: human embryonic stem cells-derived endothelial cells, hiPSC-EC: human 
induced pluripotent stem cells-derived endothelial cells  
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6.  Discussion 
 
 
Cardiovascular ischemic diseases are leading cause of death worldwide. Peripheral 
arterial diseases and post infarction cardiomyopathy have high burdens on health and 
social care. In myocardial infarction ~1 billion cardiomyocytes suffer definite necrosis. 
After ischemic attack, only small amount of the injured tissue can regenerate from the 
stunned state. Regenerative capacity of the myocardium is inefficient to maintain left 
ventricular function. Myocardial inflammation, fibrosis, scar formation and remodelling 
occur. These pathological conditions result in vicious circle leading to severe ischemic 
cardiomyopathy with left ventricular remodelling and insufficiency. Albeit, 
pharmacological modulation of the renin-angiotensin-aldosterone system, beta receptor 
inhibition and statin therapy are beneficial on mortality outcomes and also have moderate 
effects on reverse remodelling. Definite therapy to improve reduced myocardial function 
and replace injured cardiomyocytes and endothelial cells is lacking. In the last decades 
many cell types were investigated as future candidate for cardiovascular cell therapy. Early 
investigation focused on cardiac resident stem cells, endothelial progenitor cells, bone 
marrow-derived mononuclear cells and MSC. First clinical trials ended with moderate or 
non-beneficial outcome; furthermore, many of those published conflicting data [98]. To 
eliminate doubts on the effects of bone marrow-derived mononuclear cells and MSC 
implantation in acute MI and heart failure, large, randomised clinical trials are underway 
(BAMI, CHART-1/2). Early studies with these cell types have reported mild or no increase 
in left ventricular function, exact transdifferentiation of these cells to cardiomyocytes is 
doubtful. Beneficial effects of MSC transplantation seem to lie in their paracrine, anti-
inflammatory, anti-fibrotic and reverse remodelling effects. Large individual variability 
exists in these regenerative mechanisms. Thus, a cardiac index was recently set to 
characterise responder status of patients before MSC transplantation [110]. 
Human pluripotent stem cells have become a focus of regenerative medicine. Human iPSC 
seem to be promising cell type for cardiovascular regeneration. The ideal cell type for 
regenerative purposes would be easily available, easy to collect and expand, should have 
stable karyotype and phenotype, should be efficiently and feasibly differentiated towards 
the desired cell type, may not be immunogenic and must provide desired functional activity 
in vivo. In the early steps of cardiovascular regenerative medicine researchers first must 
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define the most appropriate differentiation protocols in vitro. Then in vitro studies must be 
completed to study phenotype, gene expression profile and functional activity of these 
cells. Preclinical in vivo experiments should demonstrate feasibility and safety of cell 
transplatation before human application.  
Results from this project increase our knowledge on the characteristics and behaviour of 
cardiovascular derivatives of human pluripotent stem cells. Characterisation of hESC and 
hiPSC proved that these colonies possess pluripotent markers. Undifferentiated stem cells 
were successfully differentiated towards mesodermal and endothelial lineage. Preclinical 
small animal experiments call for large animal studies to move toward cardiovascular 
tissue engineering and human applications. 
Recent studies focused on hiPSC which offer unique platform for patient specific disease 
modelling and drug testing [171]. Yamanaka developed first induced pluripotent stem cells 
from adult somatic fibroblasts. His publication was a clear breakthrough in regenerative 
medicine and stem cell research [80]. Since then, reprogramming methods have been 
continuously developing. Here we successfully developed hiPSC from human adult 
somatic fibroblasts. Cardiovascular derivatives of these cells offer platform for patient and 
disease specific investigations in vitro. In my studies healthy volunteers were fibroblast 
donors, but success of hIPSC development warrants further studies on patient specific 
induced pluripotent stem cells-derived. 
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6.1.  Endothelial characteristics and functional activity 
 
Human pluripotent stem cells-derived endothelial cells showed similar 
characteristics in vitro as mature endothelial cells. Their phenotype, immunocytochemical 
properties and gene expression profile were comperable with those in HUVEC. When 
endothelial cells were grown under shear stress, human aortic endothelial cells and blood 
outgrowth endothelial cells were elongated and aligned in the direction of shear. By 
contrast, hESC-EC did not align in the direction of shear stress. These observations show 
differences in endothelial cells derived from embryonic stem cells versus those from blood 
progenitor cells and large vessels. The differences in in vitro behaviour may suggest that 
endothelial cells from different sources and human embryonic stem cells not posses same 
phenotype in vitro. Human pluripotent stem cell derivatives may not have adult, mature 
phenotype in vitro, thus in vivo conditioning should be needed for further maturing.  
Beside abundant expression of general endothelial markers, arterial and venous genes were 
also expressed in hESC-EC and hiPSC-EC. These results suggest that endothelial 
differentiation generated mixed endothelial cultures, without significant changes between 
arterial and venous marker gene expressions.  
To study the functional properties of hESC-EC, hiPSC-EC and control endothelial cells 
proteome profiling assays and anticlotting assays were performed. Human ESC-EC and 
hiPSC-EC are able to fulfil therapeutic expectations only when they possess sufficient 
functional activity to support the physiological mechanisms of the vascular system. During 
tissue engineering, vascularisation and endothelialisation is a cornerstone towards 
therapeutic applications. Endothelial cells should provide an antithrombotic surface to line 
vessel walls. Furthermore, they play central role in inflammatory mechanisms, monocyte 
adhesion, extravasation and scar healing.  
 
6.1.1.  Proteomics 
 
Proteome profiling showed that hESC-EC and hiPSC-EC express in cell lysates and 
secrete into the supernatant many angiogenesis-related proteins, cytokines, hormones and 
soluble receptors. Analysing the expression pattern of these proteins revealed differences 
in hPSC-EC and control HCAEC. Expression levels in hESC-EC and hiPSC-EC showed 
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strong parallel pattern, suggesting that endothelial cells from different human pluripotent 
stem cell lineages may have similar functional characteristics in vivo. A population of 
peptides was also recognized which showed marked differences to those in control, adult, 
mature HCAEC. Expression levels of EGF, FGF1 and FGF2 were lower than in control 
HCAEC. These factors are important regulators of angiogenesis, wound healing and 
endothelial proliferation. Distinct expression profile suggests varying regulatory pathways 
in hESC-EC and hiPSC-EC. Other important regulators on angiogenesis and endothelial 
behaviour showed higher expression levels in hESC-EC, hiPSC-EC. These are isoforms of 
VEGF, Angiopoietin1, 2 and Activin2. However, the level of Vasohibin, a strong negative 
regulator of angiogenesis, also showed a distinct expression pattern in hESC-EC and 
hiPSC-EC.  
We have also found that hESC-EC do not produce significant amount of ET-1 which is 
central player in pulmonary hypertension and vascular inflammation [199]. Thus, hESC-
EC may be favourable for these therapeutic concerns. Furthermore hESC-EC produces 
high amount of prostacyclin which regulates endothelium-dependent and independent 
vasoactive responses on resistance arteries. Earlier studies showed that reactive oxygen 
species act via prostacyclin-derivatives in post capillary veins [200]. 
These results suggest that developed endothelial cells are highly active in expressing and 
secreting angiogenesis-related and inflammatory proteins. Thus, they may act as 
underlying signalling elements in paracrine mechanisms in vivo. The signalling pathways 
in hESC-EC and hiPSC-EC show differences when compared to mature endothelial cells, 
this emphasises the need for detailed investigations on behaviour and function of hESC-EC 
and hiPSC-EC. 
 
6.1.2.  Anticlotting properties of hESC-EC and hiPSC-EC 
 
Rantes ELISA assays revealed strong anticlotting effects of hESC-EC and hiPSC-
EC in 3D cell culture conditions. Rantes, or so called CCL5 chemokine is secreted from 
activated platelets and also have functional role in inflammatory mechanism. We 
performed experiments to measure Rantes levels in hPSC and in their endothelial 
derivatives. Scientific data are lacking regarding Rantes production in hPSC. Here we 
found similar levels of Rantes in hPSC supernatant and those in hESC-EC, hiPSC-EC and 
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HUVEC, without any significant difference. Rantes may play crucial role in regulation of 
tumour angiogenesis and formation of metastases. Recent study emphasized its role in 
ovarian cancer metastasis and suggested targeting CCL5/NFkappaB signalling pathway as 
a therapeutic target to prevent metastasis formation [201]. Another study also suggested 
regulatory role for Rantes in neoangiogenesis in chondrosarcoma [202]. Here we showed 
that hESC-EC and hiPSC-EC decrease Rantes levels in platelet rich plasma, suggesting 
decreased amount of activated platelets and increased anticlotting effects. 3D culture 
conditions enhance anticlotting effects of hESC-EC and hiPSC-EC. This enhancement in 
functional activity may be favourable when considering scale-up for vascular tissue 
engineering. As Rantes is also related to angiogenic mechanisms, its modulation by hESC-
EC and hiPSC-EC emphasises their strong angiogenic characteristics. 
 
6.2.  Arterial and venous endothelial subpopulations 
 
Development of the vascular tree and the specification of arterial, venous and 
lymphatic endothelial cells are determined genetically [176, 203, 204]. However 
environmental factors may alter endothelial fate [203]. After embryonic development of 
vascular structures, organ-specific properties of endothelial cells are gained through 
environmental signalling, e.g. blood flow, vessel wall shear stress, cell junction molecules 
and paracrine factors from surrounding tissues [203]. Endothelial cells in brain-blood 
barrier, in hepatic sinusoids, renal tubule or in coronary arteries have far more different 
functional tasks. These special characteristics are gained via environmental influencing 
factors [203]. During endothelial development, arterial and venous fate is determined in the 
early stages before the development of the embryonic heart and blood flow. This is 
suggested by my results showing that no significant difference was found in arterial and 
venous gene expression with the use of different cell culture conditions during 
differentiation. However slight changes in arterial and venous marker gene expression 
were found in different developmental protocols, suggesting that cell culture conditions 
and modulation of key signalling pathways may alter endothelial phenotype in vitro. 
During endothelial development arterial and venous fate is determined in early steps before 
embryonic heart and blood flow develops [176]. EphrinB2/EphB4 ratio is regulating 
arterial and venous segregation in heterogeneous endothelial populations during embryonic 
DOI:10.14753/SE.2016.1894
103 
 
development [205]. In our studies EphrinB2/EphB4 ratio in hESC-EC and hiPSC-EC 
revealed that endothelial cells may stand closer to arterial phenotype. Although arterial 
endothelial markers were expressed also on HUVEC cells, their regulatory profile 
suggested venous phenotype, due to the low EphrinB2/EphB4 ratio. Lymphatic endothelial 
cells develop later from the venous network [176]. Lymphatic markers were never detected 
in my experiments, suggesting that hESC-EC and hiPSC-EC stand on early maturing steps 
of developmental procedure, as lymphatic endothelial cells develop only late from venous 
cells.  
During vasculogenesis, tip arterial endothelial cells are the main regulators of arch 
development. It has so far been proven that the VEGF/Tie-2 and Notch1 signalling 
pathways trigger tip cells to initiate development of novel branches during sprouting 
angiogenesis [206]. Stalk cells are bystanders in this process. Arterial endothelial marker 
DLL4 is abundantly expressed in tip cells during vasculogenesis in the zebrafish [204]. 
After VEGF signalling on tip cells, DLL4 expression increases and activates Notch 
signalling in stalk cells to enhance development of functional branches. In my experiments 
strong expression of DLL4 on hESC-EC and hiPSC-EC suggested that endothelial 
specification occurs without environmental signal. Culturing pure arterial endothelial cells 
and using them for further tissue engineering experiments may further enhance the 
therapeutic applications of hESC-EC and hiPSC-EC. Since arterial endothelial cells are 
more atheroprotective and venous endothelial cells are more atheroprone, arterial 
endothelial cells would be preferable in many clinical scenarios. According to other studies 
VEGF signalling ought to induce arterial development in vivo [206]. In my endothelial 
differentiation studies, a strong external VEGF signal did not result in significantly higher 
levels of arterial endothelial cells compared to other differentiation protocols. These results 
suggest that signalling pathways responsible for this process have altered mechanisms of 
action in vitro. This finding proves on the one hand that HUVEC is a neonatal endothelial 
cell line with high plasticity. On the other hand, it suggests that altered environmental 
circumstances may influence HUVEC phenotype and gene expression during culturing in 
vitro. According to latest data from the literature, signalling through the VEGF-DLL4-
Notch1 pathway has a pathological role on endothelial progenitor cells in preeclampsia 
[207]. Furthermore DLL4 is targeted in cancer therapy to prevent neoangiogenesis on 
immature vasculature of tumour tissue [208]. DLL4 inhibition results in EphrinB2 
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downregulation and inhibition of neoangiogenesis in mouse tumour models [209]. These 
findings enhance the potential therapeutic use of DLL4/EphrinB2 blockade in human 
malignant diseases. Understanding their regulatory role in hESC-EC and hiPSC-EC is 
crucial to evaluate their underlying role in future therapies. 
 
6.3.  Regulatory mechanisms of endothelial differentiation, behaviour and 
specification via the PI3K/FOXO1A signalling pathway 
 
Earlier studies emphasised that the VEGF and PI3K/ERK/MAPK signalling 
pathway may have distinct regulatory roles in endothelial development [210]. Activation of 
the ERK pathway resulted in strong upregulation of arterial differentiation, while 
activation of the PI3K/Akt pathway resulted in downstream of arterial specification [211]. 
Here we showed that the PI3K/ERK/MAPK signalling pathway has regulatory role on 
human pluripotent stem cells-derived endothelial cells as well. Upregulation of FOXO1A, 
resulted in significant decrease in all endothelial marker genes. Levels of general 
endothelial markers and lineage specific arterial and venous endothelial markers were 
decreased. FOXO1A upregulation also resulted in robust decrease in arterial and venous 
endothelial ratio (EphrinB2:EphB4). Members of FOXO family have transcriptional role 
on regulation of vasculo- and angiogenesis and endothelial behaviour [176]. 
In this study I showed that PI3K pathway is one of the key intracellular signalling 
mechanisms which have wide-ranging effects on endothelial differentiation of hESC as 
well as cell death, proliferation and angiogenic activity of generated hESC-EC partially 
through FOXO1A transcription factor. The role of PI3K in generating new endothelial 
cells was supported by our observation that hESC differentiation towards endothelial 
lineage is accompanied with marked changes in expression of most of the genes related to 
PI3K/FOXO1A pathways. FOXO1A was shown to be the most abundant FOXO member 
at mRNA levels in undifferentiated hESC colonies and alteration of FOXO1A causes 
different expression of pluripotency genes in hESC, indicating that FOXO1A has a critical 
role in the regulation of hESC fate [212]. Indeed, here we showed that high FOXO1A 
expression was significantly downregulated during embryoid body formation and further 
differentiation into endothelial cells. Changes in expression also correlated with loss of 
pluripotency markers. By using a gene expression array of PI3K pathway elements, 
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Ingenuity Pathway Analysis with a curated database and subsequent clustering as an 
exploratory tool, we identified connections between FOXO1A and VEGF as well as 
various further angiogenic factors. Time development during differentiation modulated the 
expression of angiogenic factors clustered with FOXO1A such as PDK1 which play a role 
in vascular remodelling and endothelial differentiation [213]; cdc42, known to mediate 
tubulogenesis [214]; protein kinase C beta, being a stimulus for endothelial proliferation 
[215]; and activation of Rheb/mTOR for endothelial cell transformation [216]. As a 
potential result of these interactions, we found that inhibition of PI3K and consequent re-
activation of FOXO1A by LY294002 resulted in an increased number of newly formed 
endothelial cells. Higher FOXO1A levels were accompanied with increasing CD31 and 
angiopoietin-2 expression levels in the differentiating culture. This suggests an indirect 
link between FOXO1A levels and the propensity of differentiating hESC towards 
endothelial lineage. However, the fact that the control endothelial HUVEC expressed 
FOXO1A at a higher level than hESC-EC suggests that post-transcriptional control of 
FOXO1A is more important in HUVEC than those in hESC-EC. The role of FOXO1A in 
endothelial development was further evidenced by siRNA silencing experiments. Directly 
targeting FOXO1A factor decreased expression of endothelial markers and angiogenesis 
genes. This also suggests that culture medium containing VEGF and other endothelial 
cytokines may be potent stimulus for endothelial differentiation where PI3K/FOXO1A 
pathway, at least in part, mediates these signals. This is similar to other studies, where 
VEGF was shown to increase the yield of adult endothelial cells in differentiated hESC 
culture [217] and can also favour endothelial cell survival, proliferation and cell cycle 
progression via the PI3K/Akt pathway during tissue regeneration and disease [218, 219]. 
Intact PI3K signalling as well as low but detectable FOXO1A levels may be prerequisite 
for endothelial differentiation. However, our data suggest a different regulatory role for 
PI3K/FOXO1A in differentiating ESC and ESC-derived endothelial cells where FOXO1A 
has mainly inhibitory feedback signal. We characterized the temporal expression of 
FOXO1A and angiopoietin-2. Angiopoietin-2 is important target gene for FOXO1A [220-
222] and related to angiogenesis and vascular remodelling, during in vivo differentiation 
and maturation of hESC-EC. Three weeks after transplantation of hESC-EC into athymic 
nude rats, cells showed engraftment and were detectable with histology. As opposed to 
HUVEC, we detected an increase in angiopoietin-2 expression, with no significant change 
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in FOXO1A levels in hESC-EC. In vitro differentiation of hESC generated a unique 
endothelial cell type, where FOXO1A levels are significantly lower than those in control 
HUVEC, endothelial cells derived from human umbilical cord vein. This may suggest that 
these cells retain low FOXO1A levels and a controllable angiogenic activity even after in 
vivo conditioning. On contrary, we found that activation of FOXO1A by LY294002 
blocked tube formation in culture. This activity may be further modulated by the 
component that inhibition of PI3K and consequent activation of FOXO1A by LY294002 
was also found to block proliferation of hESC-EC. In line with this, earlier study showed 
that overexpression of FOXO1 inhibited endothelial tube formation and migration partly 
via direct inhibition of endothelial nitric oxide synthase [223]. FOXO proteins were shown 
to be involved in response to oxidative stress, in regulation of apoptosis and cell survival 
[223-225]. In line with these reports, here we showed that FOXO1A mediates danger 
signals such as oxidative stress by H2O2 in hESC-EC. Indeed, activation of FOXO1A 
nuclear translocation by H2O2 was accompanied with cell loss, necrosis and nuclear 
remodelling in a dose-dependent manner. Furthermore, overexpression of FOXO1A 
construct showed direct pro-necrotic effects and cell loss in hESC-EC cultures. The fact 
that FOXO1A expression levels stayed low during cell transplantation may suggests that 
these cells have lower responsiveness to in vivo danger signals. On the other hand, we 
found that silencing of FOXO1A had no protective effect on stress responsiveness of 
hESC-EC in vitro, which altogether suggests the presence of a broader regulation 
involving other, FOXO1A-independent pathways in stress-responsiveness in hESC-EC. 
LY294002 is one of the potent and specific cell-permeable inhibitor of PI3K [226]. We 
have found that inhibition of PI3K pathway by LY294002 further increased loss of hESC-
EC in oxidative stress. This observation may be in line with earlier animal studies where 
development of dermal toxicity was an in vivo side effect of LY294002 in murine model 
[227]; together with low solubility and bioavailability prevented its use in clinical trials. 
However, several further compounds are being developed to inhibit different nodes of the 
PI3K pathway. These mainly PI3K/Akt/mTOR inhibitors showed no unexpected toxic 
effects [228]. It is still unclear whether downregulation of PI3K signalling will be 
sufficient to produce a clinical response. In conclusion, human embryonic stem cell-
derived endothelial cells represent a unique endothelial population, with controllable 
proliferative and angiogenic activities. PI3K/FOXO1A pathway is one of the particular key 
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signalling elements for function and survival of hESC-EC but also in regulation of 
endothelial cell fate. We found that activated FOXO1A has various effects in hESC-EC: it 
mediates endothelial generation; on the other hand, FOXO1A, at least partly, inhibits 
proliferation and angiogenic activity, and plays a role in oxidative stress. To test whether 
using of cells along with direct pharmacological inhibition of FOXO to release negative 
feedback may be advantageous in cell therapy still need to be determined. Role of 
PI3K/FOXO1A on endothelial development and function is summarized on Figure 43. 
 
 
Figure 43. Summary figure of endothelial differentiation and specification Figure 
shows modulation of PI3K/FOXO1A pathway during endothelial differentiation and 
regulatory signals of arterial and venous endothelial specification. PI3K: 
phosphatidylinositol-4, 5-bisphosphate 3-kinase, P-FOXO1A: phosphorylated-FOXO1A, 
Angp2: Angiopoietin-2  
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6.4.  Limitations 
 
Limitations of my studies are including limited number of available human 
pluripotent stem cell lines. My experiments were performed on three pluripotent stem cell 
lines (hESC line H7 (WiCell) and hiPSC lines IMR90-40 (WiCell) and ReproCell line. A 
more robust understanding of endothelial development may require further pluripotent 
stem cell lines. Human IPS lines from patient with cardiovascular diseases may enhance 
detailed observations on pathophysiological steps in vitro. 
Endothelial differentiation procedure was performed in vitro in 2D and 3D cell culture 
circumstances. Investigation of signalling pathways and endothelial subpopulations was 
performed in 2D and 3D endothelial differentiation conditions in vitro, which are unable to 
entirelly mimic in vivo conditions during embryonic development of vessels.   
Use of hiPSC for research purposes solves ethical concerns about hESC. Although, hiPSC 
research need wise considerations, as genetic and epigenetic modifications may occur 
during reprogramming procedure.  
Many studies reported that hPSC derivatives possess different characteristics than adult 
counterpart cell types. Thus, in vitro disease modelling and drug testing also need to be 
thoroughly overviewed.  
According to our results, hPSC derivatives do not present an adult, mature cell type, albeit 
they get through maturation during in vivo conditioning. More complex transplantation 
procedure (e.g. into the hear)t would be informative to gain information on organotypic 
endothelial cell production. 
Equivalence assessment of hESC-EC, hiPSC-EC, HUVEC, HAEC, HCAEC, BOEC and 
other endothelial cells from different sources is needed. 
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7.  Conclusions 
 
Cardiovascular derivatives of human pluripotent stem cells pave the way towards 
cell therapy in cardiovascular diseases.  
During my PhD studies endothelial derivatives of hESC-EC and hiPSC-EC were studied. 
First pluripotent fate of hESC and hiPSC were featured. Reprogramming human adult 
fibroblast to pluripotent state was performed, resulting hiPSC. This result facilitate future 
patient specific disease modelling, drug testing in vitro. Next endothelial differentiation 
procedures were investigated to optimise endothelial differentiation in vitro. Efficient 
differentiation protocols are required to develop mature endothelial cells. In my studies cell 
culture conditions, effects of normoxia and hypoxia were investigated. Understanding 
endothelial differentiation conditions enhances establishment of efficient amount and 
functional of endothelial cell.  
Detailed endothelial characteristics were obtained to study phenotype, immoncytochemical 
profile, secretion and expression of angiogenesis-related proteins and endothelial gene 
expression profile. General endothelial markers, arterial and venous endothelial 
subpopulations were also analysed. Further arterial and venous endothelial ratio 
(EphrinB2/EphB4) was studied. Understanding endothelial subpopulations enhance cell 
therapy efforts, regarding distinct functional activity of arterial and venous endothelial 
cells. Arterial and venous phenotype may differ on single cell properties, furthermore 
endothelial cells may behave different and form distinct subpopulations in vitro. Role of 
the PI3K/FOXO1A signalling pathway was studied on endothelial differentiation, 
proliferation, survival, angiogenesis, arterial and venous subpopulations. Results proved 
that the PI3K/FOXO1A pathway have significant role on these.  Activation of FOXO1A 
resulted in increased CD31 positive endothelial cells yield after differentiation, decreased 
endothelial proliferation rate and inhibited tube formation on Matrigel. Inhibition of 
FOXO1A decreased CD31 and angiopoietin-2 mRNA levels, increased proliferative 
activity and increased tube formation on hESC-EC (Figure 44.). 
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Figure 44. Modulation of PI3K/FOXO1A signalling pathway Summary figure shows 
effects of FOXO1A activation via LY 294002 and FOXOA1 inhibition via FOXO1A 
siRNA treatment on hESC-EC differentiation, proliferation and tube formation. PI3K: 
phosphatidylinositol-4, 5-bisphosphate 3-kinase  
(original figure is from Edit Gara)  
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8. Summary 
 
Endothelial derivatives of human pluripotent stem cells may offer regenerative 
treatments in ischemic cardiovascular diseases. We studied role of PI3K/FOXO1A 
pathways during differentiation, proliferation, maturation and cell death on hPSC-EC. 
Endothelial differentiation conditions were optimised. Both hESC-EC and hiPSC-EC 
showed mature endothelial characteristics such as cobblestone pattern, ac-LDL uptake, and 
tube formation in vitro. During differentiation expression of FOXO1A transcription factor 
was linked to the expression of a cluster of angiogenesis- and vascular remodeling-related 
genes. PI3K inhibitor (LY294002) induced formation of CD31 positive cells. In contrast, 
differentiating with silenced FOXO1A showed lower mRNA levels of CD31 and 
angiopoietin-2. LY294002 decreased proliferative activity of purified hESC-EC, while 
FOXO1A siRNA increased their proliferation. LY294002 inhibits migration and tube 
formation; in contrast, FOXO1A siRNA increased in vitro tube formation activity. 
Proteome profiling revealed high abundance of angiogenesis-related proteins in the cell 
lysates and supernatant. Expressions of arterial (EphrinB2, Notch1-2) and venous (EphB4) 
endothelial markers were increased, suggesting the presence of mixed endothelial 
population in culture. qRT-PCR analyses in transfected cells proved that universal and 
specific arterial and venous endothelial marker genes were downregulated in high 
FOXO1A group. For engineering 3D vascular constructs biomatrices were repopulated 
with hESC-EC and hiPSC-EC. Cells remained viable on engineered matrices. Imaging 
with Calcein AM live staining and 3D Histech analysis proved monolayer-like CD31 
positive, live endothelial culture on biomatrices. After in vivo conditioning of cells in 
athymic nude rats, cells retain their low FOXO1A expression levels. Expression levels of 
general endothelial marker genes and arterial and venous endothelial markers increased 
during in vivo conditioning. PI3K/FOXO1A pathway is important for function and survival 
of hESC-EC/hiPSC-EC and in the regulation of endothelial cell fate. In-depth analyses of 
hESC-EC and hiPSC-EC, regarding phenotype specification and functional characteristics 
may enhance their application for preclinical vascular tissue engineering purposes.  
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Összefoglalás 
 
A pluripotens őssejtek kardiovaszkuláris származékai ígéretes lehetőséget 
jelentenek az iszkémiás kardiovaszkuláris betegségek sejtterápiás gyógyításában. Munkám 
során a PI3K/FOXO1A jelátviteli út szabályozó szerepét vizsgáltam az őssejt eredetű 
endothelsejtek differenciációjában, proliferációjában, érésében és sejthalálozásban. A 
humán embrionális és indukált pluripotens őssejt eredetű endothelsejtek (hESC-EC, 
hiPSC-EC) felnőtt endothelsejtekre jellemző tulajdonságokkal rendelkeztek: utcakő 
rajzolat in vitro, ac-LDL felvétel és tubulus képzés. Szoros összefüggést találtunk a 
FOXO1A transzkripciós faktor és angiogenezishez kapcsolódó transzkripciós faktorok 
expressziójában az endothel differenciáció során. A PI3K gátlás (LY294002) növelte a 
CD31 pozitív sejtek arányát a differenciáció során. A FOXO1A csendesítés csökkentette a 
CD31 és angiopoietin-2 mRNS szinteket hESC-EC és hiPSC-EC sejtekben. LY294002 
csökkentette a proliferációs képességet, FOXO1A siRNS kezelés ugyanakkor növelte a 
sejtek proliferációját. LY294002 gátolta a sejtmigrációt és tubulus formaló képességet, 
FOXO1A siRNS kezelés növelte a tubulus képző aktivitást. A sejtek fehérje profil 
vizsgálata igazolta, hogy a hESC-EC és hiPSC-EC sejtek nagy mennyiségben 
expresszálnak és szekretálnak angiogenezishez köthető fehérjéket. A hESC-EC és hiPSC-
EC sejtek egyaránt expresszáltak artériás (EphrinB2) és vénás (EphB4, Notch1-2) 
endotheliális markereket. Eredményeim vegyes, artériás és vénás endothel populációk 
jelenlétére utalnak. FOXO1A transzfekció hatására az általános és artériás, vénás endothel 
markerek szintje szignifikánsan csökkent.  
hESC-EC és hiPSC-EC sejteket 3D környezetben vizsgáltam extracelluláris mátrixon 
tenyésztve. A sejtek életképesek maradtak és funkcionális aktivitással rendelkeztek a 3D 
környezetben, így például thrombocyta aggregáció gátló hatásuk fokozódott a 3D 
sejttenyésztési környezetben. A hESC-EC és hiPSC-EC sejtek in vivo transzplantációja 
során emelkedtek az álalános és artériás, vénás endothel markerek szintjei. A 
PI3K/FOXO1A jelátviteli út jelentős szerepet játszik a hESC-EC és hiPSC-EC sejtek 
differenciációjában, fenotípusában és funkcionális tulajdonságaiban. A hESC-EC és 
hiPSC-EC sejtek tulajdonságainak részletes vizsgálata előmozdítja a sejtek jövőbeni 
terápiás felhasználását szövetépítési eljárások céljából. 
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